NZ738372B2 - Platelet storage methods and compositions for same - Google Patents
Platelet storage methods and compositions for same Download PDFInfo
- Publication number
- NZ738372B2 NZ738372B2 NZ738372A NZ73837215A NZ738372B2 NZ 738372 B2 NZ738372 B2 NZ 738372B2 NZ 738372 A NZ738372 A NZ 738372A NZ 73837215 A NZ73837215 A NZ 73837215A NZ 738372 B2 NZ738372 B2 NZ 738372B2
- Authority
- NZ
- New Zealand
- Prior art keywords
- composition
- platelets
- platelet
- inhibitor
- rhoa
- Prior art date
Links
- 210000001772 Blood Platelets Anatomy 0.000 title claims abstract description 184
- 239000000203 mixture Substances 0.000 title claims abstract description 141
- 238000003860 storage Methods 0.000 title claims description 46
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 117
- 239000003112 inhibitor Substances 0.000 claims abstract description 108
- 101700020165 RHOA Proteins 0.000 claims abstract description 62
- 102100004989 RHOA Human genes 0.000 claims abstract description 39
- 238000005057 refrigeration Methods 0.000 claims abstract description 18
- 239000011780 sodium chloride Substances 0.000 claims description 65
- 150000003839 salts Chemical class 0.000 claims description 55
- 230000004083 survival Effects 0.000 claims description 32
- 239000000969 carrier Substances 0.000 claims description 17
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 17
- 239000003795 chemical substances by application Substances 0.000 claims description 15
- 239000003814 drug Substances 0.000 claims description 14
- 230000003902 lesions Effects 0.000 claims description 14
- 108010043137 Actomyosin Proteins 0.000 claims description 12
- 238000006116 polymerization reaction Methods 0.000 claims description 12
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 12
- 239000000243 solution Substances 0.000 claims description 12
- 230000000996 additive Effects 0.000 claims description 10
- WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 9
- 229960001031 Glucose Drugs 0.000 claims description 9
- 239000000654 additive Substances 0.000 claims description 9
- UIIMBOGNXHQVGW-UHFFFAOYSA-M buffer Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 9
- 239000011734 sodium Substances 0.000 claims description 9
- WQZGKKKJIJFFOK-VFUOTHLCSA-N β-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 9
- GUBGYTABKSRVRQ-YOLKTULGSA-N Maltose Natural products O([C@@H]1[C@H](O)[C@@H](O)[C@H](O)O[C@H]1CO)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 GUBGYTABKSRVRQ-YOLKTULGSA-N 0.000 claims description 8
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims description 8
- 239000004615 ingredient Substances 0.000 claims description 7
- PYMYPHUHKUWMLA-LMVFSUKVSA-N aldehydo-D-ribose Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 claims description 6
- 239000008103 glucose Substances 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 102000005890 Spectrin Human genes 0.000 claims description 5
- 108010019965 Spectrin Proteins 0.000 claims description 5
- 230000000254 damaging Effects 0.000 claims description 5
- 150000002500 ions Chemical class 0.000 claims description 5
- FBPFZTCFMRRESA-KAZBKCHUSA-N D-Mannitol Natural products OC[C@@H](O)[C@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KAZBKCHUSA-N 0.000 claims description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 4
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L MgCl2 Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 claims description 4
- 102000004243 Tubulin Human genes 0.000 claims description 4
- 108090000704 Tubulin Proteins 0.000 claims description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-M acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 4
- 238000001802 infusion Methods 0.000 claims description 4
- 229910052943 magnesium sulfate Inorganic materials 0.000 claims description 4
- CSNNHWWHGAXBCP-UHFFFAOYSA-L magnesium sulphate Substances [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 claims description 4
- 235000019341 magnesium sulphate Nutrition 0.000 claims description 4
- 239000000594 mannitol Substances 0.000 claims description 4
- 235000010355 mannitol Nutrition 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 200000000002 platelet activation Diseases 0.000 claims description 4
- 239000001103 potassium chloride Substances 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 4
- 229940098773 Bovine Serum Albumin Drugs 0.000 claims description 3
- 108091003117 Bovine Serum Albumin Proteins 0.000 claims description 3
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 claims description 3
- JKMHFZQWWAIEOD-UHFFFAOYSA-N HEPES Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 claims description 3
- 229960002160 Maltose Drugs 0.000 claims description 3
- 239000007975 buffered saline Substances 0.000 claims description 3
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 claims description 3
- 229910001424 calcium ion Inorganic materials 0.000 claims description 3
- 239000008151 electrolyte solution Substances 0.000 claims description 3
- 229960001855 mannitol Drugs 0.000 claims description 3
- 239000003002 pH adjusting agent Substances 0.000 claims description 3
- 239000002953 phosphate buffered saline Substances 0.000 claims description 3
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 claims description 3
- 229910052708 sodium Inorganic materials 0.000 claims description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 claims description 3
- 239000003381 stabilizer Substances 0.000 claims description 3
- 239000008223 sterile water Substances 0.000 claims description 3
- NIJJYAXOARWZEE-UHFFFAOYSA-N Depacane Chemical compound CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 claims description 2
- 239000007995 HEPES buffer Substances 0.000 claims description 2
- 229940037179 Potassium Ion Drugs 0.000 claims description 2
- UPMFZISCCZSDND-JJKGCWMISA-M Sodium gluconate Chemical compound [Na+].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O UPMFZISCCZSDND-JJKGCWMISA-M 0.000 claims description 2
- 229940005574 Sodium gluconate Drugs 0.000 claims description 2
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K Trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 claims description 2
- 239000001110 calcium chloride Substances 0.000 claims description 2
- 229910001628 calcium chloride Inorganic materials 0.000 claims description 2
- 235000011148 calcium chloride Nutrition 0.000 claims description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 claims description 2
- JLVVSXFLKOJNIY-UHFFFAOYSA-N magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 claims description 2
- 229910001425 magnesium ion Inorganic materials 0.000 claims description 2
- 239000006179 pH buffering agent Substances 0.000 claims description 2
- NPYPAHLBTDXSSS-UHFFFAOYSA-N potassium ion Chemical compound [K+] NPYPAHLBTDXSSS-UHFFFAOYSA-N 0.000 claims description 2
- 229910001414 potassium ion Inorganic materials 0.000 claims description 2
- FKNQFGJONOIPTF-UHFFFAOYSA-N sodium cation Chemical compound [Na+] FKNQFGJONOIPTF-UHFFFAOYSA-N 0.000 claims description 2
- 239000001509 sodium citrate Substances 0.000 claims description 2
- 239000000176 sodium gluconate Substances 0.000 claims description 2
- 235000012207 sodium gluconate Nutrition 0.000 claims description 2
- 229910001415 sodium ion Inorganic materials 0.000 claims description 2
- 239000001488 sodium phosphate Substances 0.000 claims description 2
- 229910000162 sodium phosphate Inorganic materials 0.000 claims description 2
- 108010065972 tick anticoagulant peptide Proteins 0.000 claims description 2
- 239000003656 tris buffered saline Substances 0.000 claims description 2
- 239000011778 trisodium citrate Substances 0.000 claims description 2
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 claims description 2
- 108050001278 CDC42 Proteins 0.000 abstract description 30
- RXIUMAOXORBRCY-UHFFFAOYSA-N 2-[(6-phenyl-2,3,4,9-tetrahydro-1H-carbazol-1-yl)amino]ethanol Chemical group OCCNC1CCCC(C2=C3)=C1NC2=CC=C3C1=CC=CC=C1 RXIUMAOXORBRCY-UHFFFAOYSA-N 0.000 abstract description 22
- 210000004369 Blood Anatomy 0.000 abstract description 6
- 239000008280 blood Substances 0.000 abstract description 6
- 239000003937 drug carrier Substances 0.000 abstract 2
- -1 Rac Proteins 0.000 description 84
- 125000000217 alkyl group Chemical group 0.000 description 55
- 230000000694 effects Effects 0.000 description 34
- 125000003118 aryl group Chemical group 0.000 description 25
- 150000002632 lipids Chemical class 0.000 description 24
- 101700065091 rho1 Proteins 0.000 description 23
- 125000001153 fluoro group Chemical group F* 0.000 description 22
- 125000003545 alkoxy group Chemical group 0.000 description 21
- 125000005843 halogen group Chemical group 0.000 description 21
- 125000001424 substituent group Chemical group 0.000 description 21
- 125000004093 cyano group Chemical group *C#N 0.000 description 20
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 18
- 102000011068 Cdc42 Human genes 0.000 description 17
- 102000008186 Collagen Human genes 0.000 description 16
- 108010035532 Collagen Proteins 0.000 description 16
- 125000004432 carbon atoms Chemical group C* 0.000 description 16
- 229960005188 collagen Drugs 0.000 description 16
- 229920001436 collagen Polymers 0.000 description 16
- 230000002441 reversible Effects 0.000 description 16
- 102100007785 RHOD Human genes 0.000 description 15
- 239000012528 membrane Substances 0.000 description 14
- 239000002253 acid Substances 0.000 description 13
- 230000004913 activation Effects 0.000 description 13
- 230000015572 biosynthetic process Effects 0.000 description 13
- 108010085238 Actins Proteins 0.000 description 12
- 102000007469 Actins Human genes 0.000 description 12
- 125000004122 cyclic group Chemical group 0.000 description 12
- 125000000753 cycloalkyl group Chemical group 0.000 description 12
- 238000005755 formation reaction Methods 0.000 description 12
- 102000036113 Rho family Human genes 0.000 description 11
- 108091018292 Rho family Proteins 0.000 description 11
- 229910052799 carbon Inorganic materials 0.000 description 11
- 150000001875 compounds Chemical class 0.000 description 11
- 238000011084 recovery Methods 0.000 description 11
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 10
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 10
- 239000000126 substance Substances 0.000 description 10
- 125000003342 alkenyl group Chemical group 0.000 description 9
- 125000001072 heteroaryl group Chemical group 0.000 description 9
- 125000000623 heterocyclic group Chemical group 0.000 description 9
- 102000013446 GTP Phosphohydrolases Human genes 0.000 description 8
- 108091006093 GTPases Proteins 0.000 description 8
- 102000003886 Glycoproteins Human genes 0.000 description 8
- 108090000288 Glycoproteins Proteins 0.000 description 8
- 210000001178 Neural Stem Cells Anatomy 0.000 description 8
- OKTJSMMVPCPJKN-UHFFFAOYSA-N carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 8
- 230000001419 dependent Effects 0.000 description 8
- 230000002265 prevention Effects 0.000 description 8
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 7
- 229910052739 hydrogen Inorganic materials 0.000 description 7
- 108020003175 receptors Proteins 0.000 description 7
- 102000005962 receptors Human genes 0.000 description 7
- 229940035295 Ting Drugs 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 210000004027 cells Anatomy 0.000 description 6
- 230000001404 mediated Effects 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 6
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 5
- 238000007792 addition Methods 0.000 description 5
- 230000027455 binding Effects 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N diethyl ether Chemical class CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 5
- 229940079593 drugs Drugs 0.000 description 5
- 125000005842 heteroatoms Chemical group 0.000 description 5
- 239000001257 hydrogen Substances 0.000 description 5
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 229910052757 nitrogen Inorganic materials 0.000 description 5
- 230000011664 signaling Effects 0.000 description 5
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 description 4
- 210000004292 Cytoskeleton Anatomy 0.000 description 4
- 229940012952 Fibrinogen Drugs 0.000 description 4
- 108010049003 Fibrinogen Proteins 0.000 description 4
- 102000008946 Fibrinogen Human genes 0.000 description 4
- 229940019698 Fibrinogen containing hemostatics Drugs 0.000 description 4
- 206010057249 Phagocytosis Diseases 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 230000002776 aggregation Effects 0.000 description 4
- 238000004220 aggregation Methods 0.000 description 4
- 150000001412 amines Chemical group 0.000 description 4
- 125000004429 atoms Chemical group 0.000 description 4
- 239000002585 base Substances 0.000 description 4
- 230000003436 cytoskeletal Effects 0.000 description 4
- 125000004435 hydrogen atoms Chemical group [H]* 0.000 description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
- 150000007522 mineralic acids Chemical class 0.000 description 4
- 238000003032 molecular docking Methods 0.000 description 4
- 150000007524 organic acids Chemical class 0.000 description 4
- 150000007530 organic bases Chemical class 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- MYMOFIZGZYHOMD-UHFFFAOYSA-N oxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 4
- 230000008782 phagocytosis Effects 0.000 description 4
- 235000021317 phosphate Nutrition 0.000 description 4
- 125000006239 protecting group Chemical group 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- NINIDFKCEFEMDL-UHFFFAOYSA-N sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 4
- 229910052717 sulfur Inorganic materials 0.000 description 4
- 239000011593 sulfur Substances 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 3
- 239000004475 Arginine Substances 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 206010022114 Injury Diseases 0.000 description 3
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 3
- 210000002381 Plasma Anatomy 0.000 description 3
- 125000005631 S-sulfonamido group Chemical group 0.000 description 3
- 102100002147 SLC2A4RG Human genes 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N acetic acid ethyl ester Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 150000001336 alkenes Chemical class 0.000 description 3
- 150000001345 alkine derivatives Chemical group 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-O ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 3
- 150000003863 ammonium salts Chemical class 0.000 description 3
- 230000001580 bacterial Effects 0.000 description 3
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- 231100000673 dose–response relationship Toxicity 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 108040001860 guanyl-nucleotide exchange factor activity proteins Proteins 0.000 description 3
- 230000003834 intracellular Effects 0.000 description 3
- 239000006166 lysate Substances 0.000 description 3
- AFVFQIVMOAPDHO-UHFFFAOYSA-N methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000006011 modification reaction Methods 0.000 description 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 3
- 235000005985 organic acids Nutrition 0.000 description 3
- IPCSVZSSVZVIGE-UHFFFAOYSA-N palmitic acid group Chemical group C(CCCCCCCCCCCCCCC)(=O)O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 238000010379 pull-down assay Methods 0.000 description 3
- 230000001105 regulatory Effects 0.000 description 3
- BZKBCQXYZZXSCO-UHFFFAOYSA-N sodium hydride Chemical compound [H-].[Na+] BZKBCQXYZZXSCO-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 125000002813 thiocarbonyl group Chemical group *C(*)=S 0.000 description 3
- NKCXQMYPWXSLIZ-PSRDDEIFSA-N (2S)-2-[[(2S)-1-[(2S)-5-amino-2-[[2-[[(2S)-6-amino-2-[[2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S,3R)-2-amino-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-3-hydroxybutanoyl]amino]propanoyl]amino]-4-oxobutanoyl]amino]-3-m Chemical compound O=C([C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](N)[C@@H](C)O)[C@@H](C)O)C(C)C)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O NKCXQMYPWXSLIZ-PSRDDEIFSA-N 0.000 description 2
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 description 2
- VDFVNEFVBPFDSB-UHFFFAOYSA-N 1,3-dioxane Chemical compound C1COCOC1 VDFVNEFVBPFDSB-UHFFFAOYSA-N 0.000 description 2
- IMLSAISZLJGWPP-UHFFFAOYSA-N 1,3-dithiolane Chemical compound C1CSCS1 IMLSAISZLJGWPP-UHFFFAOYSA-N 0.000 description 2
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K 2qpq Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- OEYIOHPDSNJKLS-UHFFFAOYSA-N C[N+](C)(C)CCO Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 2
- 229960001231 Choline Drugs 0.000 description 2
- IAKHMKGGTNLKSZ-INIZCTEOSA-N Colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 2
- ZBCBWPMODOFKDW-UHFFFAOYSA-N Diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 2
- 101700043311 GGTA1 Proteins 0.000 description 2
- 102000016285 Guanine Nucleotide Exchange Factors Human genes 0.000 description 2
- 108010067218 Guanine Nucleotide Exchange Factors Proteins 0.000 description 2
- XKMLYUALXHKNFT-UUOKFMHZSA-N Guanosine-5'-triphosphate Chemical class C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XKMLYUALXHKNFT-UUOKFMHZSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- RAXXELZNTBOGNW-UHFFFAOYSA-N Imidazole Chemical compound C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- 101700056668 MTA1 Proteins 0.000 description 2
- 101710045190 MTLA2 Proteins 0.000 description 2
- 241000282560 Macaca mulatta Species 0.000 description 2
- 210000002284 Membrane Microdomains Anatomy 0.000 description 2
- 229920000789 Polyinosinic:polycytidylic acid Polymers 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N Salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 102000003838 Sialyltransferases Human genes 0.000 description 2
- 108090000141 Sialyltransferases Proteins 0.000 description 2
- 208000010110 Spontaneous Platelet Aggregation Diseases 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- 108090000190 Thrombin Proteins 0.000 description 2
- 108090000992 Transferases Proteins 0.000 description 2
- 102000004357 Transferases Human genes 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K [O-]P([O-])([O-])=O Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 150000001242 acetic acid derivatives Chemical class 0.000 description 2
- 230000002378 acidificating Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 125000002252 acyl group Chemical group 0.000 description 2
- 150000001447 alkali salts Chemical class 0.000 description 2
- 125000004647 alkyl sulfenyl group Chemical group 0.000 description 2
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 2
- 125000002947 alkylene group Chemical group 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 description 2
- 125000005110 aryl thio group Chemical group 0.000 description 2
- 125000004104 aryloxy group Chemical group 0.000 description 2
- 150000003851 azoles Chemical class 0.000 description 2
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 2
- 150000001642 boronic acid derivatives Chemical class 0.000 description 2
- 150000001649 bromium compounds Chemical class 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 125000002837 carbocyclic group Chemical group 0.000 description 2
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 description 2
- 150000002315 glycerophosphates Chemical class 0.000 description 2
- 150000002430 hydrocarbons Chemical group 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- 125000002883 imidazolyl group Chemical group 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N indole Chemical class C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- 150000004694 iodide salts Chemical class 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 101700072735 lys-1 Proteins 0.000 description 2
- 159000000003 magnesium salts Chemical class 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 2
- 239000011859 microparticle Substances 0.000 description 2
- 125000002911 monocyclic heterocycle group Chemical group 0.000 description 2
- 125000001624 naphthyl group Chemical group 0.000 description 2
- 150000002823 nitrates Chemical class 0.000 description 2
- GRYLNZFGIOXLOG-UHFFFAOYSA-N nitric acid Chemical class O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
- WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical compound C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 2
- 229940115272 poly I:C Drugs 0.000 description 2
- 238000002203 pretreatment Methods 0.000 description 2
- WTKZEGDFNFYCGP-UHFFFAOYSA-N pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N pyrrole Chemical class C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- RWRDLPDLKQPQOW-UHFFFAOYSA-N pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 2
- 230000002829 reduced Effects 0.000 description 2
- 102000007268 rho GTP-Binding Proteins Human genes 0.000 description 2
- 108010033674 rho GTP-Binding Proteins Proteins 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- 150000003871 sulfonates Chemical class 0.000 description 2
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N t-BuOH Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 230000001225 therapeutic Effects 0.000 description 2
- 125000003396 thiol group Chemical group [H]S* 0.000 description 2
- 229960004072 thrombin Drugs 0.000 description 2
- 230000003582 thrombocytopenic Effects 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 2
- 125000005152 trihalomethanesulfonyl group Chemical group 0.000 description 2
- 125000006527 (C1-C5) alkyl group Chemical group 0.000 description 1
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 description 1
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 description 1
- WTGVJERCTXWBLZ-BTJKTKAUSA-N (Z)-but-2-enedioic acid;2-hydroxybenzoic acid Chemical compound OC(=O)\C=C/C(O)=O.OC(=O)C1=CC=CC=C1O WTGVJERCTXWBLZ-BTJKTKAUSA-N 0.000 description 1
- SPEUIVXLLWOEMJ-UHFFFAOYSA-N 1,1-dimethoxyethane Chemical compound COC(C)OC SPEUIVXLLWOEMJ-UHFFFAOYSA-N 0.000 description 1
- LSPHULWDVZXLIL-UHFFFAOYSA-L 1,2,2-trimethylcyclopentane-1,3-dicarboxylate Chemical class CC1(C)C(C([O-])=O)CCC1(C)C([O-])=O LSPHULWDVZXLIL-UHFFFAOYSA-L 0.000 description 1
- UGUHFDPGDQDVGX-UHFFFAOYSA-N 1,2,3-thiadiazole Chemical compound C1=CSN=N1 UGUHFDPGDQDVGX-UHFFFAOYSA-N 0.000 description 1
- YGTAZGSLCXNBQL-UHFFFAOYSA-N 1,2,4-thiadiazole Chemical compound C=1N=CSN=1 YGTAZGSLCXNBQL-UHFFFAOYSA-N 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N 1,2-ethanediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- CIISBYKBBMFLEZ-UHFFFAOYSA-N 1,2-oxazolidine Chemical compound C1CNOC1 CIISBYKBBMFLEZ-UHFFFAOYSA-N 0.000 description 1
- LKLLNYWECKEQIB-UHFFFAOYSA-N 1,3,5-triazinane Chemical compound C1NCNCN1 LKLLNYWECKEQIB-UHFFFAOYSA-N 0.000 description 1
- MGNZXYYWBUKAII-UHFFFAOYSA-N 1,3-Cyclohexadiene Chemical compound C1CC=CC=C1 MGNZXYYWBUKAII-UHFFFAOYSA-N 0.000 description 1
- WNXJIVFYUVYPPR-UHFFFAOYSA-N 1,3-dioxolane Chemical compound C1COCO1 WNXJIVFYUVYPPR-UHFFFAOYSA-N 0.000 description 1
- 125000006091 1,3-dioxolane group Chemical class 0.000 description 1
- ABADUMLIAZCWJD-UHFFFAOYSA-N 1,3-dioxole Chemical compound C1OC=CO1 ABADUMLIAZCWJD-UHFFFAOYSA-N 0.000 description 1
- WQADWIOXOXRPLN-UHFFFAOYSA-N 1,3-dithiane Chemical compound C1CSCSC1 WQADWIOXOXRPLN-UHFFFAOYSA-N 0.000 description 1
- IVJFXSLMUSQZMC-UHFFFAOYSA-N 1,3-dithiole Chemical compound C1SC=CS1 IVJFXSLMUSQZMC-UHFFFAOYSA-N 0.000 description 1
- QVFHFKPGBODJJB-UHFFFAOYSA-N 1,3-oxathiane Chemical compound C1COCSC1 QVFHFKPGBODJJB-UHFFFAOYSA-N 0.000 description 1
- WJJSZTJGFCFNKI-UHFFFAOYSA-N 1,3-oxathiolane Chemical compound C1CSCO1 WJJSZTJGFCFNKI-UHFFFAOYSA-N 0.000 description 1
- UVJHQYIOXKWHFD-UHFFFAOYSA-N 1,4-Cyclohexadiene Chemical compound C1C=CCC=C1 UVJHQYIOXKWHFD-UHFFFAOYSA-N 0.000 description 1
- JBYHSSAVUBIJMK-UHFFFAOYSA-N 1,4-oxathiane Chemical compound C1CSCCO1 JBYHSSAVUBIJMK-UHFFFAOYSA-N 0.000 description 1
- VFWCMGCRMGJXDK-UHFFFAOYSA-N 1-Chlorobutane Chemical class CCCCCl VFWCMGCRMGJXDK-UHFFFAOYSA-N 0.000 description 1
- UPHOPMSGKZNELG-UHFFFAOYSA-M 1-carboxynaphthalen-2-olate Chemical class C1=CC=CC2=C(C([O-])=O)C(O)=CC=C21 UPHOPMSGKZNELG-UHFFFAOYSA-M 0.000 description 1
- VUQPJRPDRDVQMN-UHFFFAOYSA-N 1-chlorooctadecane Chemical class CCCCCCCCCCCCCCCCCCCl VUQPJRPDRDVQMN-UHFFFAOYSA-N 0.000 description 1
- WLXGQMVCYPUOLM-UHFFFAOYSA-M 1-hydroxyethanesulfonate Chemical class CC(O)S([O-])(=O)=O WLXGQMVCYPUOLM-UHFFFAOYSA-M 0.000 description 1
- HUHXLHLWASNVDB-UHFFFAOYSA-N 2-(oxan-2-yloxy)oxane Chemical compound O1CCCCC1OC1OCCCC1 HUHXLHLWASNVDB-UHFFFAOYSA-N 0.000 description 1
- MTNDZQHUAFNZQY-UHFFFAOYSA-N 2-Imidazoline Chemical compound C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 1
- WMPPDTMATNBGJN-UHFFFAOYSA-N 2-Phenylethylbromide Chemical class BrCCC1=CC=CC=C1 WMPPDTMATNBGJN-UHFFFAOYSA-N 0.000 description 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N 2-Pyrrolidone Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
- IZXIZTKNFFYFOF-UHFFFAOYSA-N 2-oxazolidone Chemical compound O=C1NCCO1 IZXIZTKNFFYFOF-UHFFFAOYSA-N 0.000 description 1
- IMSODMZESSGVBE-UHFFFAOYSA-N 2-oxazoline Chemical compound C1CN=CO1 IMSODMZESSGVBE-UHFFFAOYSA-N 0.000 description 1
- KPGXRSRHYNQIFN-UHFFFAOYSA-L 2-oxoglutarate(2-) Chemical class [O-]C(=O)CCC(=O)C([O-])=O KPGXRSRHYNQIFN-UHFFFAOYSA-L 0.000 description 1
- RSEBUVRVKCANEP-UHFFFAOYSA-N 2-pyrroline Chemical compound C1CC=CN1 RSEBUVRVKCANEP-UHFFFAOYSA-N 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N 289-95-2 Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- BCHZICNRHXRCHY-UHFFFAOYSA-N 2H-oxazine Chemical compound N1OC=CC=C1 BCHZICNRHXRCHY-UHFFFAOYSA-N 0.000 description 1
- ZRPLANDPDWYOMZ-UHFFFAOYSA-M 3-cyclopentylpropanoate Chemical class [O-]C(=O)CCC1CCCC1 ZRPLANDPDWYOMZ-UHFFFAOYSA-M 0.000 description 1
- 125000004208 3-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C([H])C(*)=C1[H] 0.000 description 1
- 125000004207 3-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(OC([H])([H])[H])=C1[H] 0.000 description 1
- WEQPBCSPRXFQQS-UHFFFAOYSA-N 4,5-dihydro-1,2-oxazole Chemical compound C1CC=NO1 WEQPBCSPRXFQQS-UHFFFAOYSA-N 0.000 description 1
- 125000004801 4-cyanophenyl group Chemical group [H]C1=C([H])C(C#N)=C([H])C([H])=C1* 0.000 description 1
- 125000004203 4-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 1
- UCZQXJKDCHCTAI-UHFFFAOYSA-N 4H-1,3-dioxine Chemical compound C1OCC=CO1 UCZQXJKDCHCTAI-UHFFFAOYSA-N 0.000 description 1
- MRUWJENAYHTDQG-UHFFFAOYSA-N 4H-pyran Chemical compound C1C=COC=C1 MRUWJENAYHTDQG-UHFFFAOYSA-N 0.000 description 1
- GDRVFDDBLLKWRI-UHFFFAOYSA-N 4H-quinolizine Chemical compound C1=CC=CN2CC=CC=C21 GDRVFDDBLLKWRI-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- HNYOPLTXPVRDBG-UHFFFAOYSA-N Barbituric acid Chemical compound O=C1CC(=O)NC(=O)N1 HNYOPLTXPVRDBG-UHFFFAOYSA-N 0.000 description 1
- JYZIHLWOWKMNNX-UHFFFAOYSA-N Benzimidazole Chemical compound C1=C[CH]C2=NC=NC2=C1 JYZIHLWOWKMNNX-UHFFFAOYSA-N 0.000 description 1
- KTZQTRPPVKQPFO-UHFFFAOYSA-N Benzisoxazole Chemical class C1=CC=C2C=NOC2=C1 KTZQTRPPVKQPFO-UHFFFAOYSA-N 0.000 description 1
- IANQTJSKSUMEQM-UHFFFAOYSA-N Benzofuran Chemical class C1=CC=C2OC=CC2=C1 IANQTJSKSUMEQM-UHFFFAOYSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- FCEHBMOGCRZNNI-UHFFFAOYSA-N Benzothiophene Chemical class C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 description 1
- 210000001217 Buttocks Anatomy 0.000 description 1
- 125000006577 C1-C6 hydroxyalkyl group Chemical group 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L Calcium hydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 235000007575 Calluna vulgaris Nutrition 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- WCZVZNOTHYJIEI-UHFFFAOYSA-N Cinnoline Chemical compound N1=NC=CC2=CC=CC=C21 WCZVZNOTHYJIEI-UHFFFAOYSA-N 0.000 description 1
- 230000037250 Clearance Effects 0.000 description 1
- DMEGYFMYUHOHGS-UHFFFAOYSA-N Cycloheptane Chemical compound C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 description 1
- ZXIJMRYMVAMXQP-UHFFFAOYSA-N Cycloheptene Chemical compound C1CCC=CCC1 ZXIJMRYMVAMXQP-UHFFFAOYSA-N 0.000 description 1
- HGCIXCUEYOPUTN-UHFFFAOYSA-N Cyclohexene Chemical compound C1CCC=CC1 HGCIXCUEYOPUTN-UHFFFAOYSA-N 0.000 description 1
- ZSWFCLXCOIISFI-UHFFFAOYSA-N Cyclopentadiene Chemical compound C1C=CC=C1 ZSWFCLXCOIISFI-UHFFFAOYSA-N 0.000 description 1
- LPIQUOYDBNQMRZ-UHFFFAOYSA-N Cyclopentene Chemical compound C1CC=CC1 LPIQUOYDBNQMRZ-UHFFFAOYSA-N 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical class C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- OIVLITBTBDPEFK-UHFFFAOYSA-N Dihydrouracil Chemical compound O=C1CCNC(=O)N1 OIVLITBTBDPEFK-UHFFFAOYSA-N 0.000 description 1
- KPUWHANPEXNPJT-UHFFFAOYSA-N Disiloxane Chemical class [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 description 1
- JKFAIQOWCVVSKC-UHFFFAOYSA-N Furazan Chemical compound C=1C=NON=1 JKFAIQOWCVVSKC-UHFFFAOYSA-N 0.000 description 1
- 102100003517 GP1BA Human genes 0.000 description 1
- 101700034668 GP1BA Proteins 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-N Gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 1
- 210000003958 Hematopoietic Stem Cells Anatomy 0.000 description 1
- 210000003494 Hepatocytes Anatomy 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- AWJUIBRHMBBTKR-UHFFFAOYSA-N Isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 1
- ZLTPDFXIESTBQG-UHFFFAOYSA-N Isothiazole Chemical compound C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 description 1
- CTAPFRYPJLPFDF-UHFFFAOYSA-N Isoxazole Chemical class C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 1
- 241000229754 Iva xanthiifolia Species 0.000 description 1
- HBBGRARXTFLTSG-UHFFFAOYSA-N Lithium Ion Chemical compound [Li+] HBBGRARXTFLTSG-UHFFFAOYSA-N 0.000 description 1
- 210000002540 Macrophages Anatomy 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N Meglumine Chemical class CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- FEWJPZIEWOKRBE-XIXRPRMCSA-N Mesotartaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-XIXRPRMCSA-N 0.000 description 1
- 108091022031 Microtubules Proteins 0.000 description 1
- 102000028664 Microtubules Human genes 0.000 description 1
- 210000004688 Microtubules Anatomy 0.000 description 1
- 241000353097 Molva molva Species 0.000 description 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-Acetylglucosamine Chemical group CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
- HZAXFHJVJLSVMW-UHFFFAOYSA-O NCC[OH2+] Chemical compound NCC[OH2+] HZAXFHJVJLSVMW-UHFFFAOYSA-O 0.000 description 1
- ODUCDPQEXGNKDN-UHFFFAOYSA-N Nitroxyl Chemical compound O=N ODUCDPQEXGNKDN-UHFFFAOYSA-N 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N P-Toluenesulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 241000282320 Panthera leo Species 0.000 description 1
- 241000282520 Papio Species 0.000 description 1
- NRNCYVBFPDDJNE-UHFFFAOYSA-N Pemoline Chemical compound O1C(N)=NC(=O)C1C1=CC=CC=C1 NRNCYVBFPDDJNE-UHFFFAOYSA-N 0.000 description 1
- 229960000761 Pemoline Drugs 0.000 description 1
- VLTRZXGMWDSKGL-UHFFFAOYSA-M Perchlorate Chemical class [O-]Cl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-M 0.000 description 1
- LFSXCDWNBUNEEM-UHFFFAOYSA-N Phthalazine Chemical compound C1=NN=CC2=CC=CC=C21 LFSXCDWNBUNEEM-UHFFFAOYSA-N 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-N Picric acid Chemical compound OC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-N 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N Potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 210000001243 Pseudopodia Anatomy 0.000 description 1
- CPNGPNLZQNNVQM-UHFFFAOYSA-N Pteridine Chemical compound N1=CN=CC2=NC=CN=C21 CPNGPNLZQNNVQM-UHFFFAOYSA-N 0.000 description 1
- KDCGOANMDULRCW-UHFFFAOYSA-N Purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 1
- DNXIASIHZYFFRO-UHFFFAOYSA-N Pyrazoline Chemical compound C1CN=NC1 DNXIASIHZYFFRO-UHFFFAOYSA-N 0.000 description 1
- PBMFSQRYOILNGV-UHFFFAOYSA-N Pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 1
- JWVCLYRUEFBMGU-UHFFFAOYSA-N Quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 description 1
- XSCHRSMBECNVNS-UHFFFAOYSA-N Quinoxaline Chemical compound N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 description 1
- 101700023645 RAC1 Proteins 0.000 description 1
- 102100002253 RAC1 Human genes 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N Rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 210000003518 Stress Fibers Anatomy 0.000 description 1
- KZNICNPSHKQLFF-UHFFFAOYSA-N Succinimide Chemical compound O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 description 1
- DHXVGJBLRPWPCS-UHFFFAOYSA-N THP Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 1
- RAOIDOHSFRTOEL-UHFFFAOYSA-N Tetrahydrothiophene Chemical compound C1CCSC1 RAOIDOHSFRTOEL-UHFFFAOYSA-N 0.000 description 1
- OGYGFUAIIOPWQD-UHFFFAOYSA-N Thiazolidine Chemical compound C1CSCN1 OGYGFUAIIOPWQD-UHFFFAOYSA-N 0.000 description 1
- CBDKQYKMCICBOF-UHFFFAOYSA-N Thiazoline Chemical compound C1CN=CS1 CBDKQYKMCICBOF-UHFFFAOYSA-N 0.000 description 1
- RVBUGGBMJDPOST-UHFFFAOYSA-N Thiobarbituric acid Chemical compound O=C1CC(=O)NC(=S)N1 RVBUGGBMJDPOST-UHFFFAOYSA-N 0.000 description 1
- BRNULMACUQOKMR-UHFFFAOYSA-N Thiomorpholine Chemical compound C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Tris Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 241000256856 Vespidae Species 0.000 description 1
- 150000008043 acidic salts Chemical class 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000003213 activating Effects 0.000 description 1
- 125000002015 acyclic group Chemical group 0.000 description 1
- 125000005354 acylalkyl group Chemical group 0.000 description 1
- 102000035425 adaptor proteins Human genes 0.000 description 1
- 108091005736 adaptor proteins Proteins 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical class [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 125000005036 alkoxyphenyl group Chemical group 0.000 description 1
- 125000004448 alkyl carbonyl group Chemical group 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- 125000004644 alkyl sulfinyl group Chemical group 0.000 description 1
- 125000004414 alkyl thio group Chemical group 0.000 description 1
- 125000005466 alkylenyl group Chemical group 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 125000004103 aminoalkyl group Chemical group 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 1
- 230000002429 anti-coagulation Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 210000001219 anucleate thrombocyte Anatomy 0.000 description 1
- 125000005099 aryl alkyl carbonyl group Chemical group 0.000 description 1
- 125000003710 aryl alkyl group Chemical group 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 125000003289 ascorbyl group Chemical class [H]O[C@@]([H])(C([H])([H])O*)[C@@]1([H])OC(=O)C(O*)=C1O* 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-L aspartate group Chemical class N[C@@H](CC(=O)[O-])C(=O)[O-] CKLJMWTZIZZHCS-REOHCLBHSA-L 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical class [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 230000013926 blood microparticle formation Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 150000004648 butanoic acid derivatives Chemical class 0.000 description 1
- HQABUPZFAYXKJW-UHFFFAOYSA-O butylazanium Chemical compound CCCC[NH3+] HQABUPZFAYXKJW-UHFFFAOYSA-O 0.000 description 1
- 230000001275 ca(2+)-mobilization Effects 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- FBEDQOZZWWECAJ-UHFFFAOYSA-M calcium;magnesium;hydroxide Chemical compound [OH-].[Mg+2].[Ca+2] FBEDQOZZWWECAJ-UHFFFAOYSA-M 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-M camphorsulfonate anion Chemical class C1CC2(CS([O-])(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-M 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-M caproate Chemical class CCCCCC([O-])=O FUZZWVXGSFPDMH-UHFFFAOYSA-M 0.000 description 1
- 150000001720 carbohydrates Chemical group 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 230000032677 cell aging Effects 0.000 description 1
- 230000001413 cellular Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 230000035512 clearance Effects 0.000 description 1
- 229960001338 colchicine Drugs 0.000 description 1
- PMPVIKIVABFJJI-UHFFFAOYSA-N cyclobutane Chemical compound C1CCC1 PMPVIKIVABFJJI-UHFFFAOYSA-N 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- UKJLNMAFNRKWGR-UHFFFAOYSA-N cyclohexatrienamine Chemical group NC1=CC=C=C[CH]1 UKJLNMAFNRKWGR-UHFFFAOYSA-N 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- RGSFGYAAUTVSQA-UHFFFAOYSA-N cyclopentane Chemical compound C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- LVZWSLJZHVFIQJ-UHFFFAOYSA-N cyclopropane Chemical compound C1CC1 LVZWSLJZHVFIQJ-UHFFFAOYSA-N 0.000 description 1
- GBOGMAARMMDZGR-TYHYBEHESA-N cytochalasin B Chemical compound C([C@H]1[C@@H]2[C@@H](C([C@@H](O)[C@@H]3/C=C/C[C@H](C)CCC[C@@H](O)/C=C/C(=O)O[C@@]23C(=O)N1)=C)C)C1=CC=CC=C1 GBOGMAARMMDZGR-TYHYBEHESA-N 0.000 description 1
- 230000001086 cytosolic Effects 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 150000008050 dialkyl sulfates Chemical class 0.000 description 1
- MHDVGSVTJDSBDK-UHFFFAOYSA-N dibenzyl ether Chemical class C=1C=CC=CC=1COCC1=CC=CC=C1 MHDVGSVTJDSBDK-UHFFFAOYSA-N 0.000 description 1
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-O diethylazanium Chemical compound CC[NH2+]CC HPNMFZURTQLUMO-UHFFFAOYSA-O 0.000 description 1
- LCGLNKUTAGEVQW-UHFFFAOYSA-N dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- SRXOCFMDUSFFAK-UHFFFAOYSA-N dimethyl peroxide Chemical compound COOC SRXOCFMDUSFFAK-UHFFFAOYSA-N 0.000 description 1
- ROSDSFDQCJNGOL-UHFFFAOYSA-O dimethylaminium Chemical compound C[NH2+]C ROSDSFDQCJNGOL-UHFFFAOYSA-O 0.000 description 1
- GAFRWLVTHPVQGK-UHFFFAOYSA-N dipentyl sulfate Chemical class CCCCCOS(=O)(=O)OCCCCC GAFRWLVTHPVQGK-UHFFFAOYSA-N 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-M dodecyl sulfate Chemical class CCCCCCCCCCCCOS([O-])(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-M 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N edta Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical class CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- QUSNBJAOOMFDIB-UHFFFAOYSA-O ethylaminium Chemical compound CC[NH3+] QUSNBJAOOMFDIB-UHFFFAOYSA-O 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N fumaric acid Chemical compound OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 150000002240 furans Chemical class 0.000 description 1
- 125000002519 galactosyl group Chemical group C1([C@H](O)[C@@H](O)[C@@H](O)[C@H](O1)CO)* 0.000 description 1
- 150000002270 gangliosides Chemical class 0.000 description 1
- 238000003209 gene knockout Methods 0.000 description 1
- 230000002068 genetic Effects 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- ZRALSGWEFCBTJO-UHFFFAOYSA-N guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002373 hemiacetals Chemical class 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-M heptanoate Chemical class CCCCCCC([O-])=O MNWFXJYAOYHMED-UHFFFAOYSA-M 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical class I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 1
- WRYCSMQKUKOKBP-UHFFFAOYSA-N imidazolidine Chemical compound C1CNCN1 WRYCSMQKUKOKBP-UHFFFAOYSA-N 0.000 description 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 230000002427 irreversible Effects 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001261 isocyanato group Chemical group *N=C=O 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000001810 isothiocyanato group Chemical group *N=C=S 0.000 description 1
- 150000003951 lactams Chemical class 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000000670 limiting Effects 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 125000000040 m-tolyl group Chemical group [H]C1=C([H])C(*)=C([H])C(=C1[H])C([H])([H])[H] 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 150000002688 maleic acid derivatives Chemical class 0.000 description 1
- PEEHTFAAVSWFBL-UHFFFAOYSA-N maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-M methanesulfonate group Chemical class CS(=O)(=O)[O-] AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- TUDYPXFSYJRWDP-UHFFFAOYSA-N methoxy methyl carbonate Chemical compound COOC(=O)OC TUDYPXFSYJRWDP-UHFFFAOYSA-N 0.000 description 1
- BAVYZALUXZFZLV-UHFFFAOYSA-O methylammonium Chemical compound [NH3+]C BAVYZALUXZFZLV-UHFFFAOYSA-O 0.000 description 1
- 230000029115 microtubule polymerization Effects 0.000 description 1
- 230000003278 mimic Effects 0.000 description 1
- 230000002438 mitochondrial Effects 0.000 description 1
- 230000000051 modifying Effects 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- YNAVUWVOSKDBBP-UHFFFAOYSA-N morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 1
- 229940113083 morpholine Drugs 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-M naphthalene-2-sulfonate Chemical class C1=CC=CC2=CC(S(=O)(=O)[O-])=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-M 0.000 description 1
- 150000002814 niacins Chemical class 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 230000003000 nontoxic Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 230000000771 oncological Effects 0.000 description 1
- 150000003891 oxalate salts Chemical class 0.000 description 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N oxazole Chemical class C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
- KVGZZAHHUNAVKZ-UHFFFAOYSA-N p-dioxin Chemical compound O1C=COC=C1 KVGZZAHHUNAVKZ-UHFFFAOYSA-N 0.000 description 1
- 125000005489 p-toluenesulfonic acid group Chemical class 0.000 description 1
- 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 description 1
- 230000001717 pathogenic Effects 0.000 description 1
- 244000052769 pathogens Species 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 235000019371 penicillin G benzathine Nutrition 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 230000002093 peripheral Effects 0.000 description 1
- JRKICGRDRMAZLK-UHFFFAOYSA-L persulfate group Chemical group S(=O)(=O)([O-])OOS(=O)(=O)[O-] JRKICGRDRMAZLK-UHFFFAOYSA-L 0.000 description 1
- 125000001792 phenanthrenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3C=CC12)* 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-M picrate anion Chemical class [O-]C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-M 0.000 description 1
- GLUUGHFHXGJENI-UHFFFAOYSA-N piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 1
- JTHRRMFZHSDGNJ-UHFFFAOYSA-N piperazine-2,3-dione Chemical compound O=C1NCCNC1=O JTHRRMFZHSDGNJ-UHFFFAOYSA-N 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 125000005547 pivalate group Chemical group 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- KYQCOXFCLRTKLS-UHFFFAOYSA-N pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- SMWDFEZZVXVKRB-UHFFFAOYSA-N quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 238000000611 regression analysis Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 101700024625 rhoaa Proteins 0.000 description 1
- 150000003873 salicylate salts Chemical class 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000005630 sialyl group Chemical group 0.000 description 1
- 101710044770 sll1951 Proteins 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 238000003033 structure based virtual screening Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 150000003890 succinate salts Chemical class 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 235000011044 succinic acid Nutrition 0.000 description 1
- 229960002317 succinimide Drugs 0.000 description 1
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002194 synthesizing Effects 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 229960001367 tartaric acid Drugs 0.000 description 1
- 150000003892 tartrate salts Chemical class 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- ILMRJRBKQSSXGY-UHFFFAOYSA-N tert-butyl(dimethyl)silicon Chemical group C[Si](C)C(C)(C)C ILMRJRBKQSSXGY-UHFFFAOYSA-N 0.000 description 1
- YPWFISCTZQNZAU-UHFFFAOYSA-N tetrahydro-2H-thiopyran Chemical compound C1CCSCC1 YPWFISCTZQNZAU-UHFFFAOYSA-N 0.000 description 1
- 125000005329 tetralinyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
- QEMXHQIAXOOASZ-UHFFFAOYSA-N tetramethylammonium Chemical class C[N+](C)(C)C QEMXHQIAXOOASZ-UHFFFAOYSA-N 0.000 description 1
- 150000003536 tetrazoles Chemical class 0.000 description 1
- 150000003567 thiocyanates Chemical class 0.000 description 1
- 125000000858 thiocyanato group Chemical group *SC#N 0.000 description 1
- YTPLMLYBLZKORZ-UHFFFAOYSA-N thiophene Chemical class C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-M toluenesulfonate group Chemical group C=1(C(=CC=CC1)S(=O)(=O)[O-])C LBLYYCQCTBFVLH-UHFFFAOYSA-M 0.000 description 1
- 125000005490 tosylate group Chemical group 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- QXTIBZLKQPJVII-UHFFFAOYSA-N triethylsilicon Chemical group CC[Si](CC)CC QXTIBZLKQPJVII-UHFFFAOYSA-N 0.000 description 1
- 125000000025 triisopropylsilyl group Chemical group C(C)(C)[Si](C(C)C)(C(C)C)* 0.000 description 1
- GETQZCLCWQTVFV-UHFFFAOYSA-O trimethylammonium Chemical compound C[NH+](C)C GETQZCLCWQTVFV-UHFFFAOYSA-O 0.000 description 1
- 125000003258 trimethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])[*:1] 0.000 description 1
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- KQBSGRWMSNFIPG-UHFFFAOYSA-N trioxane Chemical compound C1COOOC1 KQBSGRWMSNFIPG-UHFFFAOYSA-N 0.000 description 1
- ZDPHROOEEOARMN-UHFFFAOYSA-M undecanoate Chemical class CCCCCCCCCCC([O-])=O ZDPHROOEEOARMN-UHFFFAOYSA-M 0.000 description 1
- 125000004417 unsaturated alkyl group Chemical group 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000012130 whole-cell lysate Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/02—Preservation of living parts
- A01N1/0205—Chemical aspects
- A01N1/021—Preservation or perfusion media, liquids, solids or gases used in the preservation of cells, tissue, organs or bodily fluids
- A01N1/0221—Freeze-process protecting agents, i.e. substances protecting cells from effects of the physical process, e.g. cryoprotectants, osmolarity regulators like oncotic agents
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/02—Preservation of living parts
- A01N1/0205—Chemical aspects
- A01N1/021—Preservation or perfusion media, liquids, solids or gases used in the preservation of cells, tissue, organs or bodily fluids
- A01N1/0226—Physiologically active agents, i.e. substances affecting physiological processes of cells and tissue to be preserved, e.g. anti-oxidants or nutrients
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
- C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
- C07D241/40—Benzopyrazines
Abstract
Disclosed are compositions and methods for slowing, preventing, or reversing platelet damage, particularly as may occur during blood banking or during refrigeration of platelets. The composition may include one or more of a RAC inhibitor, a CDC42 inhibitor, a RHOA inhibitor (Rhosin or G04), or a combination thereof. The compositions may further include a pharmaceutically acceptable carrier. In certain embodiments, the RAC inhibitor is NSC23766, the CDC42 inhibitor is CASIN (Formula IIa), and the RHOA inhibitor is Rhosin (G04; Formula III). bination thereof. The compositions may further include a pharmaceutically acceptable carrier. In certain embodiments, the RAC inhibitor is NSC23766, the CDC42 inhibitor is CASIN (Formula IIa), and the RHOA inhibitor is Rhosin (G04; Formula III).
Description
ET STORAGE METHODS AND COMPOSITIONS FOR SAME
CROSS REFERENCE TO D APPLICATIONS
This application claims priority to and benefit of US Patent
Application Serial No. 14/743,213, filed June 18, 2015, of same title,
in its entirety for all purposes.
BACKGROUND
Patients with low platelet counts often require platelet transfusion. This
is particularly crucial in the treatment of patients with cancer or
e trauma. The use of platelet transfusions has increased
dramatically since 1980s, but a safe, long-term platelet storage method
remains unavailable. The demonstration of sful, refrigerated
storage of platelets for extended lengths of time, for example, 3’ days or
longer, would dramatically change the current practice of platelet
transfusion in the n World. Approximately 3,000,000 doses of
platelets are used in the United States every year, and account for sales
of ~$1.5 Billion annually. The current short shelf—life represents a
major handicap to convert platelet ts into ive commodities.
Depending on the time of the year, month or even week, up to 20% of
products can be wasted due to expiration. In the meantime, there are
moments of platelets shortages due to unpredictable increased usage.
The extension of platelet product shelf-life would strengthen the
national inventory of platelets for oncological and trauma patients. An
estimated 10-fold se in the need of platelet and plasma products
is expected by the US government in war casualties and massive
trauma patients due to the 1 red cellzl plateletzl plasma product
transfusion policy.
Current practice has platelets stored at 20 to 24°C after preparation,
which has a d lifetime up to 5 days, primarily due to concerns
about ial contamination. Bacterial contamination of platelet
products for usion is a major safety problem in blood g.
The consequence of transfusion of contaminated products is increased
morbi-mortality among a susceptible population of cancer patients (1).
Different technologies have been developed aiming to minimize the
risk of bacterial ination including diversion pouches for
collection, bacterial detection with automatic culture systems and
pathogen reduction systems (2—6). While there has been a icant
reduction in the number of cases of platelet transfusion associated
sepsis, the risk of transfusion-associated sepsis ranges between 1 in
,000 to 86,000 platelet transfusions (7, 8). Storage of platelets in
cold temperatures, as is done for red cells, would reduce the
proliferation of most bacteria and allow a longer period of storage (9),
minimizing the current shortages (10) that the short storage time (5-
day) for platelets approved by the FDA (11). Conventional cold
storage of platelets, however, has been ed by the discovery that
the 24-hour recovery of chilled platelets was significantly reduced
(14).
The development of a method to prevent platelet damage upon
refrigeration is a much needed, and long sought after e in blood
banking. Such development would revolutionize the current method of
platelet storage. The instant disclosure solves one or more of these
deficiencies in the art.
BRIEF SUMMARY
Disclosed are compositions and methods for one or more of slowing,
preventing, or ing platelet damage, particularly as may occur
during blood banking or during refrigeration of ets. The
composition may e one or more of a RAC inhibitor, a CDC42
inhibitor, a RHOA inhibitor, or a combination thereof. The
compositions may further include a ceutically acceptable
carrier.
BRIEF DESCRIPTION OF THE DRAWINGS
FIGS 1A— 1B depict a schematic model of “cold receptor” initiated
ellular events involving Rho GTPases. 1A. Cold causes the
actomyosin changes, Ca2+ mobilization, loss of spectrin anchorage,
and Gplb clustering. 1B. “Cold receptor” may stimulate Cdc42, Rac,
and/or Rho activation, which in turn control lipid raft assembly and
actomyesin reorganization, resulting in Gplb clustering.
FIG 2 depicts Rho GTPases inhibitor chemical structures and s.
FIGS 3A—D depict a g model of Casin bound to Cdc42 surface
groove and data demonstrating Casin activity. 3A. Docking model of
Casin bound to a Cdc42 surface groove required for activation. 3B.
Collagen—induced Cdc42 activation is inhibited by Casin (10 pM) in a
GST-PAK pulldown assay. 3C. Fibrinogen mediated platelet actin
filopedia structure is blocked by Casin (10 HM). Rhodamine
conjugated phalloidin—staining of platelets d to coated collagen
surface. 3D. Collagen d aggregation is blocked by 10 “M Casin
(upper panel) and is reversible (up to 30 uM Casin) upon a wash of the
inhibitor treated platelets (lower panel).
FIGS 4A—4E depict a docking model of Rac inhibitor NSC23766 and
data showing NSC23766 activity. 4A. X—ray ure of 66
bound to a Racl surface groove ed for GEF activation. 4B. Racl
activity is inhibited by NSC23766 (50 uM) in a GST-PAK pulldown
assay. 4C. Fibrinogen-mediated platelet actin lamellopodia structure is
blocked by NSC23766 (50 uM). ine conjugated phalloidin-
staining of platelets adhered to coated collagen surface. 4D. Collagen
induced aggregation is blocked by NSC23766 in a dose-dependent
fashion. 4E. Inhibition of collagen induced platelet aggregation by
NSC23766 (SOuM) is reversible upon a wash of the inhibitor treated
platelets.
FIGS 5A—5D depict a docking model of Rho inhibitor G04 and data
showing GO4 activity. 5A. Docking model of G04 bound to a RhoA
surface groove required for GEF tion. Upper panel: low
resolution; Lower panel: high resolution binding domain. 5B.
Collagen-induced RhoA activity is inhibited by G04 (50 uM) in a
GST-Rhotekin pulldown assay. 5C. U46629 (10 mM/Fibrinogen
(3pM)—mediated platelet actin opodia structure is blocked by
G04 (30 uM). ine conjugated phalloidin-staining of platelets
adhered to coated collagen surface. 5D. Collagen induced aggregation
is inhibited by G04 (upper panel). Similar to collagen, thrombin
d aggregation (data not shown) is blocked by G04 in a dose-
dependent fashion (upper panel) and is reversible upon a wash of the
inhibitor treated platelets (lower panel).
FIGS 6A—6D depict the effects of Rho GTPase inhibitor treatment on
platelet transfusion. 6A. Experimental s. 6B-6D. 24-hour
recovery and al of platelets in different conditions. 6B. r
recovery. 6C-6D. Platelet recovery at different time points. Donor
platelets were stored at room temperature (squares) or pretreated with a
mixed Rho GTPase inhibitors (50 uM NSC23766, 10 pM CASIN
and/or 75 ”M G04) or no drug (control). Data are presented as mean
SD. *p<0.01 (Anova test with Bonferroni correction, between
refrigerated with no inhibitor and refrigerated with triple inhibitor
combination).
FIG 7 depicts effects of Rho GTPase inhibitor combinations on platelet
survival upon transfusion. Platelet recovery at different time points is
shown. Donor platelets were stored at room room temp (squares) or
pretreated with a mixed Rho GPase tors (50 uM NSC23766, 10
uM CASIN and/or 75 uM G04) or no drug (Ctrl). Data are presented as
mean iSD. *p<0.01 (Anova test with Bonferroni correction, between
refrigeratied with no inhibitor and refrigerated with triple inhibitor
combination).
FIG 8 depicts total microparticle and G plb+ article counts from
platelets stored in different conditions. Results are representative of
three independent experiments with similar results of platelets stored
for 6 days in 50 11M NSC23766, 10 pM CASIN and/or 75 ”M G04, or
no drug (Vehicle control). The left panel shows articles/mcL of
refrigerated stored ets for 6 days; the right panel shows Gp1b+
article counts of refrigerated stored platelets for 6 days.
FIG 9 depicts amelioration of lipid raft formation by Rho GTPase
inhibitor combinations. Platelets were stored at RT or 4°C for 3 or 7
days in different combinations of inhibitors (50 ”M NSC23766, 10 pM
CASIN and/or 75 pM G04) or no drug (vehicle control) at RT or 4°C.
Platelet lysates were analyzed in the presence (lipid rafts) or absence
(whole cell lysate) of Triton-X-lOO mediated extraction. Results are
representative of two independent experiments with similar results.
Lowe panels represent normalized quantification of lipid raft
formation.
FIG lOA—lOC depicts ry (%) of human platelets transfused to
pre-treated, thrombocytopenic NSG immunodevicient mice (FIG 10A
and 10B); FIG C shows differential recovery between test and control
in a randomized, crossover trial of treated refrigerated platelets in
atologous transfusion of 7—day stored Rhesus monkey ets.
FIG 11A—11B depicts RhoA deletion (RhoAA/A) after administratoin of
poly I:C compared with pre- poly I:C RhoA expresion levels in
platelets. FIG 11B depicts Flotillin-l and actin expression in lipid rafts
(upper panel) and in whole platelet lysates (lower panel).
FIG l2A-12D depict the effect of Rho family tors on murine
wild-type and RhoA-deficient platelets (12A); the effect of Rho family
inhibitors on human ets (12B); and the effect of Rho family
inhibitors on galactosyl- (12C) and sialyl- (12D) transferase activities
to the platelet membranes.
DETAILED PTION
Unless defined otherwise, all technical and scientific terms used herein
have the same g as commonly understood by one of ordinary
skill in the art to which the embodiments belong. gh any
methods and materials similar or equivalent to those described herein
may also be used in the practice or g of the ments, the
preferred methods and materials are now described. All publications
mentioned herein are expressly incorporated by reference in their
entireties.
DEFINITIONS
It must be noted that as used herein and in the appended claims, the
singular forms “a,” “an,” and “the” include plural referents unless the
context clearly es otherwise. Thus, for example, nce to “a
et” includes a plurality of such platelets and reference to “the
carrier” includes reference to one or more carriers and equivalents
thereof known to those skilled in the art, and so forth.
The term “about” or “approximately” means within an acceptable error
range for the particular value as ined by one of ordinary skill in
the art, which will depend in part on how the value is measured or
determined, e.g., the limitations of the measurement system. For
example, “about” can mean within 1 or more than 1 standard
deviations, per the practice in the art. Where particular values are
described in the application and claims, unless otherwise stated the
term “about” meaning within an acceptable error range for the
particular value should be assumed.
An “amide” is a chemical moiety with formula —(R)n—C(O)NHR' or
—(R)n—NHC(O)R', where R and R' are independently selected from
WO 04809
the group consisting of alkyl, cycloalkyl, aryl, heteroaryl (bonded
through a ring carbon) and heteroalicyclic (bonded through a ring
carbon), and where n is 0 or 1.
The term “aromatic” refers to an aromatic group which has at least
one ring having a conjugated pi electron system and includes both
carbocyclic aryl (e.g., phenyl) and heterocych aryl groups (e.g.,
pyridine). The term es monocyclic or fused-ring polycyclic (i.e.,
rings which share adjacent pairs of carbon atoms) groups. The term
“carbocyclic” refers to a compound which contains one or more
covalently closed ring ures, and that the atoms forming the
backbone of the ring are all carbon atoms. The term thus distinguishes
carbocyclic from heterocyclic rings in which the ring backbone
contains at least one atom which is different from carbon. The term
“heteroaromatic” refers to an aromatic group which contains at least
one cyclic ring.
As used herein, the term “alkyl” refers to an tic hydrocarbon
group. The alkyl moiety may be a “saturated alky group, which
means that it does not n any alkene or alkyne moieties. The alkyl
moiety may also be an “unsaturated alkyl” moiety, which means that it
contains at least one alkene or alkyne moiety. An “alkene” moiety
refers to a group consisting of at least two carbon atoms and at least
one carbon-carbon double bond, and an “alkyne” moiety refers to a
group consisting of at least two carbon atoms and at least one carbon-
carbon triple bond. The alkyl , whether saturated or rated,
may be branched, ht chain, or cyclic.
The alkyl group may have 1 to 20 carbon atoms (whenever it appears
herein, a numerical range such as “1 to 20” refers to each integer in the
given range; e.g., “1 to 20 carbon atoms” means that the alkyl group
may consist of 1 carbon atom, 2 carbon atoms, 3 carbon atoms, etc., up
to and including 20 carbon atoms, although the present definition also
covers the occurrence of the term “alkyl” where no numerical range is
designated). The alkyl group may also be a medium size alkyl having 1
to 10 carbon atoms. The alkyl group could also be a lower alkyl having
1 to 5 carbon atoms. The alkyl group of the compounds of the
invention may be designated as “C1-C4 alkyl” or similar designations.
By way of example only, “C1-C4 alkyl” indicates that there are one to
four carbon atoms in the alkyl chain, i.e., the alkyl chain is selected
from the group consisting of methyl, ethyl, propyl, iso—propyl, n-butyl,
tyl, sec-butyl, and t-butyl.
The alkyl group may be substituted or unsubstituted. When
substituted, the substituent group(s) ) one or more group(s)
individually and ndently selected from cycloalkyl, aryl,
heteroaryl, heteroalicyclic, hydroxy, alkoxy, aryloxy, mercapto,
hio, arylthio, cyano, halo, carbonyl, thiocarbonyl, O-carbamyl,
N—carbamyl, O-thiocarbamyl, N—thiocarbamyl, C-amido, N—amido, S-
sulfonamido, N—sulfonamido, C-carboxy, O-carboxy, isocyanato,
thiocyanato, isothiocyanato, nitro, silyl, trihalomethanesulfonyl, and
amino, ing mono- and di-substituted amino groups, and the
protected derivatives thereof. Typical alkyl groups include, but are in
no way limited to, methyl, ethyl, propyl, isopropyl, butyl, isobutyl,
tertiary butyl, pentyl, hexyl, ethenyl, propenyl, l, ropyl,
utyl, cyclopentyl, cyclohexyl, and the like. Wherever a
tuent is described as being “optionally substituted” that
substitutent may be substituted with one of the above substituents.
The term “ester” refers to a chemical moiety with formula —(R)n—
COOR', where R and R' are independently selected from the group
consisting of alkyl, cycloalkyl, aryl, heteroaryl (bonded through a ring
carbon) and heteroalicyclic (bonded through a ring carbon), and where
nisOorl.
The substituent “R” appearing by itself and without a number
designation refers to a substituent selected from the group consisting of
en, alkyl, cycloalkyl, aryl, heteroaryl (bonded through a ring
carbon) and heteroalicycljc (bonded through a ring carbon).
An “O—carboxy” group refers to a RC(=O)O— group, where R is as
defined herein.
A “C-carboxy” group refers to a —C(=O)OR groups where R is as
d herein.
An “acety ” group refers to a —C(=O)CH3, group.
A “trihalomethanesulfony ” group refers to a X3CS(=O)2— group
where X is a halogen.
A “cyano” group refers to a —CN group.
An “isocyanato” group refers to a —NCO group.
A “thiocyanato” group refers to a —CNS group.
An “isothiocyanato” group refers to a —NCS group.
A “sulfinyl” group refers to a —S(=O)—R group, with R as defined
herein.
A “S-sulfonamido” group refers to a —S(=O)2NR, group, with R as
d herein.
A fonamido” group refers to a RS(=O)2NH— group with R as
defined herein.
A lomethanesulfonamido” group refers to a X3CS(=O)2NR—
group with X and R as defined herein.
An “O-carbamyl” group refers to a —OC(=O)—N(R)2, group—with R
as defined herein.
An “N—carbamyl” group refers to a ROC(=O)NH— group, with R as
defined herein.
An “O-thiocarbamyl” group refers to a —OC(=S)—N(R)2, group with
R as defined herein.
An “N—thiocarbamyl” group refers to an ROC(=S)NH— group, with R
as defined herein.
A do” group refers to a —C(=O)—N(R)2 group with R as
defined herein.
An “N—amido” group refers to a RC(=O)NH— group, with R as
defined herein.
The term “perhaloalky ” refers to an alkyl group where all of the
hydrogen atoms are replaced by halogen atoms.
The term “acylalky ” refers to a RC(=O)R'— group, with R as defined
herein, and R' being a diradical alkylene group. Examples of acylalkyl,
without limitation, may include CH3C(=O)CH2—,
CH3C(=O)CH2CH2—, CH3CH2C(=O)CH2CH2—,
CH3C(=O)CH2CH2CH2—, and the like.
Unless otherwise indicated, when a substituent is deemed to be
“optionally substituted,” it is meant that the tutent is a group that
may be substituted with one or more group(s) dually and
independently selected from cycloalkyl, aryl, heteroaryl,
heteroalicyclic, hydroxy, alkoxy, aryloxy, to, alkylthio,
arylthio, cyano, halo, yl, thiocarbonyl, O—carbamyl, amyl,
O-thiocarbamyl, N-thiocarbamyl, C-amido, N-amido, S-sulfonamido,
N—sulfonamido, C-carboxy, O-carboxy, isocyanato, thiocyanato,
isothiocyanato, nitro, silyl, trihalomethanesulfonyl, and amino,
WO 04809
including mono— and di-substituted amino groups, and the protected
tives thereof.
The terms “protecting group” and “protecting groups” as used herein
refer to any atom or group of atoms that is added to a molecule in order
to prevent existing groups in the molecule from undergoing unwanted
chemical ons. The protecting group moiety may be chosen in
such a way, that they are stable to the reaction conditions applied and
readily removed at a convenient stage using methodology known from
the art. A non-limiting list of protecting groups include ;
substituted ; alkylcarbonyls (e.g., t—butoxycarbonyl (BOC));
arylalkylcarbonyls (e.g., benzyloxycarbonyl, benzoyl); tuted
methyl ether (e.g. methoxymethyl ether); substituted ethyl ether; a
substituted benzyl ether; tetrahydropyranyl ether; silyl ethers (e.g.,
trimethylsilyl, triethylsilyl, triisopropylsilyl, t—butyldimethylsilyl, or t-
butyldiphenylsilyl); esters (e.g. benzoate ester); carbonates (e.g.
methoxymethylcarbonate); sulfonates (e.g. te, mesylate); acyclic
ketal (e.g. dimethyl acetal); cyclic ketals (e.g., 1,3-dioxane or 1,3-
dioxolanes); acyclic acetal; cyclic acetal; acyclic hemiacetal; cyclic
hemiacetal; and cyclic dithioketals (e.g., 1,3-dithiane or 1,3-
dithiolane).
As used herein, the term “cycloalkyl” is intended to cover three-, four—,
five-, six—, seven—, and eight— or more membered rings sing
carbon atoms only. A cycloalkyl can optionally contain one or more
rated bonds situated in such a way, however, that an ic pi—
on system does not arise. Some examples of “cycloalkyl” are the
carbocycles cyclopropane, cyclobutane, cyclopentane, cyclopentene,
cyclopentadiene, cyclohexane, cyclohexene, 1,3—cyclohexadiene, 1,4-
cyclohexadiene, cycloheptane, or cycloheptene.
As used herein, ocyclyl” means a cyclic ring system comprising
at least one heteroatom in the ring system backbone. The heteroatoms
are independently selected from oxygen, sulfur, and nitrogen.
Heterocyclyls may include multiple fused rings. Heterocyclyls may
have any degree of saturation provided that at least one ring in the ring
system is not aromatic. cyclyls may be substituted or
unsubstituted, and are attached to other groups via any available
valence, preferably any available carbon or en. Preferred
monocyclic heterocycles are of 5 or 6 members. In six membered
monocyclic heterocycles, the heteroatom(s) are selected from one up to
three of oxygen, sulfur, and nitrogen, and wherein when the
heterocycle is five membered, preferably it has one or two heteroatoms
selected from oxygen, sulfur, and nitrogen.
A heterocyclyl can further n one or more carbonyl or
thiocarbonyl functionalities, so as to make the definition include oxo—
systems and thio—systems such as lactams, lactones, cyclic imides,
cyclic ides, cyclic carbamates, and the like. Some examples of
“heterocyclyls” include, but are not limited to, tetrahydrothiopyran,
4H-pyran, tetrahydropyran, dine, 1,3-dioxin, 1,3-dioxane, 1,4-
dioxin, 1,4—dioxane, piperazine, 1,3-oxathiane, athiin, 1,4-
oxathiane, tetrahydro—1,4-thiazine, 2H-1,2—oxazine, maleimide,
succinimide, barbituric acid, thiobarbituric acid, dioxopiperazine,
oin, dihydrouracil, morpholine, trioxane, hexahydro—1,3,5-
triazine, tetrahydrothiophene, tetrahydrofuran, pyrroline, pyrrolidine,
pyrrolidone, pyrrolidione, pyrazoline, pyrazolidine, imidazoline,
imidazolidine, 1,3—dioxole, 1,3-dioxolane, 1,3-dithiole, 1,3-dithiolane,
isoxazoline, isoxazolidine, oxazoline, idine, oxazolidinone,
thiazoline, thiazolidine, and 1,3-oxathiolane. The attachment point of a
heterocycle radical can be at the position of a nitrogen heteroatom or
via a carbon atom of the heterocycle.
The term “ary ” means a carbocych aromatic ling or ring system.
Moreover, the term “aryl” includes fused ring systems wherein at least
two aryl rings, or at least one aryl and at least one C3-8—cycloalkyl
share at least one chemical bond. Some examples of “aryl” rings
include ally substituted phenyl, naphthalenyl, phenanthrenyl,
anthracenyl, tetralinyl, fluorenyl, indenyl, and indanyl. The term “ary ”
s to aromatic, including, for example, benzenoid groups,
ted via one of the ring-forming carbon atoms, and optionally
carrying one or more substituents selected from heterocyclyl,
heteroaryl, halo, hydroxy, amino, cyano, nitro, alkylamido, acyl, C1-6
alkoxy, C1-6 alkyl, C1-6 hydroxyalkyl, C1-6 aminoalkyl, C1-6
alkylamino, alkylsulfenyl, alkylsulfinyl, alkylsulfonyl, sulfamoyl, or
trifluoromethyl. The aryl group can be substituted at the para and/or
meta positions. In other embodiments, the aryl group can be substituted
at the ortho position. Representative examples of aryl groups include,
but are not limited to, phenyl, 3-halophenyl, 4-halophenyl, 3-
hydroxyphenyl, 4—hydroxyphenyl, 3-aminophenyl, 4-aminophenyl, 3-
methylphenyl, 4—methylphenyl, 3-methoxyphenyl, 4—methoxyphenyl,
4—trifluoromethoxyphenyl 3-cyanophenyl, 4—cyanophenyl,
dimethylphenyl, naphthyl, hydroxynaphthyl, hydroxymethylphenyl,
romethylphenyl, alkoxyphenyl, 4-morpholin-4—y1—pheny1, 4-
pyrrolidin-l-ylphenyl, 4-pyrazoly1pheny1, 4—triazoly1phenyl, and 4—(2—
oxopyrrolidin— 1-yl)phenyl.
As used herein, the term “heteroaryl” means an ic radical
having one or more heteroatom(s) (e.g., oxygen, sulfur, or nitrogen) in
the ring backbone and may include a single ring (e.g., pyridine) or
multiple condensed rings (e.g., quinoline). aryl groups can carry
one or more substituents, each independently ed from halo,
hydroxy, amino, cyano, nitro, cycloalkyl, kyl, aryl, heterocyclyl,
mercapto, alkylamido, acyl, C1—6-alkoxy, C1alkyl, C1
hydroxyalkyl, C1aminoalkyl, lkylamino, alkylsulfenyl,
ulfinyl, alkylsulfonyl, sulfamoyl, and trifluoromethyl.
Representative examples of heteroaryl groups e, but are not
limited to, optionally substituted derivatives of furan, benzofuran,
thiophene, benzothiophene, pyrrole, pyridine, indole, oxazole,
azole, isoxazole, benzisoxazole, le, hiazole,
isothiazole, imidazole, benzimidazole, pyrazole, indazole, tetrazole,
quionoline, isoquinoline, pyridazine, pyrimidine, purine and pyrazine,
furazan, 1,2,3-oxadiazole, 1,2,3-thiadiazole, 1,2,4-thiadiazole, tn'azole,
benzotn'azole, pteridine, phenoxazole, oxadiazole, benzopyrazole,
quinolizine, cinnoline, phthalazine, quinazoline, and quinoxaline. In
some embodiments, the substituents can be halo, hydroxy, cyano, O—
C1alkyl, C1-6—alkyl, hydroxy—C1a1kyl, and C1a1kyl.
The term “platelet” is used here to refer to a blood platelet. A platelet
can be described as a minisule protoplasmic disk occurring in
vertebrate blood. Platelets play a role in blood clotting. The platelet
may be d from any source including a human blood supply, or
the patient's own blood.
As used herein, the term “effective amount” means the amount of one
or more active components that is sufficient to show a desired effect.
This es both therapeutic and prophylactic effects. When applied
to an individual active ingredient, administered alone, the term refers
to that ient alone. When applied to a combination, the term
refers to combined amounts of the active ingredients that result in the
therapeutic effect, whether stered in combination, serially or
simultaneously.
Refrigerated storage is ed to reduce platelet life-span due to
sed temperature that cause glycoprotein-1b (GPIb) receptors to
cluster on specific microdomains of the platelet membrane. Applicant
has found that recognition of specific ed/syalylated residues on
clustered glycoproteins by macrophage B2 ins and hepatocyte
Ashwell—Morell receptors results in platelet phagocytosis by the host
and removal from circulation. Thus, Applicant has identified
prevention of rotein clustering as a useful target for chemical
ention.
Platelet glycoproteins are intimately associated with intracellular
cytoskeleton. Clustering of platelet glycoproteins depends on the
formation of lipid raft in the platelet membrane, which in turn depends
on the dynamics of the highly ted processes of actomyosin
assembly/disassembly. Rho family GTPases, including RhoA, Racl
and Cdc42, are a class of GTP—binding enzymes that are central
tors of F—actin polymerization/depolymerization, and have been
shown to control lipid raft formation and composition. Therefore,
Applicant postulates that changes in Rho GTPase activities may
influence platelet ne lipid raft assembly and glycoprotein
composition. Reversible targeting of Rho family GTPases by small
molecule inhibitors may prevent cytoskeleton—dependent refrigeration
storage lesions in platelets and result in increased platelet survival.
The mechanisms of how cold temperatures affect platelet survival are
not completely understood, though significant information has been
collected in the past decade. The s of cold ature on
platelets are believed to be complex and involve shape change,
cytoskeletal reorganization, activation, cell surface protein clustering
and changes in the carbohydrate structures of e glycoproteins
(15-18). Refrigeration-induced changes ing filopodia or
lamellipodia are accompanied by an increase in the fraction of total
cellular actin in a polymeric state (F—actin) (12, 18, 19) and
disappearance of a peripheral microtubule coil (20). Isolated
prevention of microtubule polymerization using colchicine has not
resulted in shape change prevention upon activation (21, 22).
Prevention of isolated actin cs using cytochalasin B s in
reversion of discoid shape (18) but not in ed et survival in
baboons (23), suggesting that irreversible blockade of actin
polymerization does not prevent the refrigeration damage.
Presence of platelet cold receptors has been postulated as an
explanation for both tatic and clinical effects when platelets are
submitted to temperatures below 16°C. Cold temperature is believed to
induce deglycosylation of glycoprotein Ib ectodomain ng N-
acetyl—D—glucosamine residues (17), which sequesters GM1
gangliosides in lipid rafts. Raft-associated glycoprotein Iba forms
clusters upon binding of 1432 adaptor proteins to its cytoplasmic
tail, a process accompanied with mitochondrial damage and PS
exposure (apoptosis—like)(24). The mechanisms of platelet clearance
are believed to be associated with lipid—raft associated GPIb clustering
and prevention of clustering prevents platelet nce (15, 25).
Intimately associated with intracellular cytoskeleton, GPIb clustering
depends on the ion of omains (so—called “lipid rafts”) in
the et ne which in turn depends on the dynamics of the
highly regulated processes of acto—myosin assembly/disassembly at
multiple levels. In summary, refrigeration results in multiple, complex
platelet s that may be closely associated with cytoskeletal
impairments at multiple levels (FIG 1A).
Actin cytoskeletal rearrangements responsible for lipid rafts and GPIb
clustering in lipid rafts depends on the coordinated activities of Cdc42,
Racl and RhoA GTPases, which control specific downstream effectors
in regulating polymerization and depoymerization of F—actin,
actomyosin contraction, tubulin polymerization, and spectrin
anchorage. The Rho family GTPases are a class of GTP—binding
enzymes that act as signaling switches in spatial/temporal transduction
and amplification of signals from platelet receptors to the intracellular
ing pathways that drive platelet function. Among the direct Rho
GTPase effectors, WASPs, forrnins and PAKs that control n
polymerization/depolymerization have been shown to be crucial in the
l of lipid raft formation and composition and tubular
polymerization of platelets (27) (FIG 1B). Therefore, changes in Rho
GTPase activities may influence platelet ne microdomain
assembly and glycoprotein composition. Earlier studies using dominant
negative mutants of Cdc42 and Racl found no effect on prevention of
cold-induced platelet damage (28), but the limitation of the tools used
has prevented investigators from manipulating actin/actomyosin
dynamics in a specific, reversible fashion.
Without intending to be limited by theory, it is believed that reversible
inhibition of multiple Rho family of GTPases by al inhibitors
can significantly improve platelet survival and transfusion on
after refrigerated storage by erence with actomyosin dynamics
and membrane microdomains to prevent GPIb clustering.
Compositions and methods useful for et survival and/or quality,
usion, and associated issues are disclosed . In one aspect, a
composition for platelet storage or treatment is described. The
composition may comprise a RAC inhibitor, for example, those
described in US. Patent No. 7,517,890 and US. Patent No. 7,612,080,
a CDC42 inhibitor, for example, those described in US. Patent No.
8,383,124; a RHOA inhibitor, and combinations thereof.
In one aspect, the RAC inhibitor may comprise a nd having the
structure of Formula I or a pharmaceutically acceptable salt thereof:
_ (Formula I)
wherein
R1 to R2 are independently selected from the group ting of H, —
X—Alk, —X—A1k-X', and —X—Y—X'; wherein
X is —CR7Rg;
X' is —CHR7R8;
Alk is a C2-C18 substituted or unsubstituted hydrocarbon chain;
Y is a C2-C3 substituted or unsubstituted alkylene chain;
R6 is H or (C1-C4) alkyl; and
R7 and R3 are independently ed from the group consisting of H
and (C1-C4) alkyl;
or a salt f;
In one aspect, the RAC inhibitor may comprise the structure of
Formula Ia or a pharmaceutically acceptable salt thereof.
(Formula Ia)
wherein:
R10 to R12 are independently selected from the group consisting of H,
halo, (C1-C4) alkyl, branched (C3-C4) alkyl, halo (C1-C4) alkyl, (C1-C4)
, N02, and NH2.
In one aspect, the RAC inhibitor may comprise Formula lb or a
pharmaceutically acceptable salt thereof.
la Ib)
In one aspect, the CDC42 inhibitor may comprise Formula II or a
pharmaceutically acceptable salt thereof.
(Formula H)
wherein
Y is selected from the group consisting of 0R7, NRgRg, and
NNR8R9;
R7 is selected from the group consisting of C1_(, alkyl, (CH2)uC3-7
cycloalkyl, C2_5 alkenyl, C1.6 alkoxy, hydroxy-C1-5 alkyl, phenyl,
C1_6 alkyl substituted with up to 5 fluoro, and C16 alkoxy
substituted with up to 5 fluoro, said C1-6 alkyl, (CH2)uC3_7
cycloalkyl, C2_(, alkenyl, C1_(, , hydroxy—C1_(, alkyl, phenyl
are each optionally substituted with one or more substituents each
independently selected from the group consisting of halo, —CN,
—OH, C1_(, alkoxyl, aryl, R19, and ORzo;
R3 and R9 may each be separately a hydrogen, or separately
selected from the group consisting of C1.6 alkyl, C34 lkyl,
and phenyl, said C1-6 alkyl, C3-7 cycloalkyl, and phenyl, each
optionally substituted with one or more substituents each
independently ed from the group consisting of halo, cyano,
nitro, hydroxy, C1_(, alkyl, —(CH2)uC3_7cycloalkyl, C2_5 alkenyl,
WO 04809
C1_6 alkoxy, hydroxy—C1-6 alkyl, R19, ORzo, C1-6 alkyl substituted
with up to 5 fluoro, and C1_(, alkoxy substituted with up to 5 fluoro,
each optionally substituted with one or more substituents each
independently selected from the group consisting of halo, cyano,
nitro, hydroxy, C1_6 alkyl, and C1_6 alkoxy; or R8 and R9 are
optionally taken together with the nitrogen to which they are
attached to form indolinyl, pyrrolidinyl, piperidinyl, piperazinyl,
or morpholinyl, each optionally substituted with one or more
substituents each ndently selected from the group consisting
of halo, cyano, nitro, hydroxy, C1_(, alkyl, (CH2)uC3_7cycloalkyl,
C24, alkenyl, C145 alkoxy, hydroxy—C1_(, alkyl, phenyl, CH; alkyl
substituted with up to 5 fluoro, and C1-6 alkoxy substituted with
up to 5 fluoro; or R8 and R2 come together to be C1_3 alkyl linking
together as a ring;
each u is independently 0, 1, 2, 3, or 4;
R2 is a hydrogen, or selected from the group consisting of C1_(,
alkyl, C3_7 lkyl, and phenyl, said C1_(, alkyl, C3_7 cycloalkyl,
and phenyl, each optionally substituted with one or more
substituents each ndently selected from the group ting
of halo, cyano, nitro, hydroxy, C1_(, alkyl, —(CH2)uC3_7 cycloalkyl,
CM alkenyl, Cm , hydroxy—C1_(, alkyl, phenyl, C1_6 alkyl
substituted with up to 5 fluoro, CH, alkoxy substituted with up to 5
fluoro, and —O(CH2)uphenyl optionally substituted with one or
more substituents each independently selected from the group
consisting of halo, cyano, nitro, hydroxy, C1_(, alkyl, and C1_(,
alkoxy; or R8 and R2 come er to be C1.3 alkyl linking
together as a ring;
R3, R4, R5 and R6 are each independently selected from the group
consisting of: hydrogen, halo, cyano, nitro, hydroxy, C 1.6 alkyl,
(CH2)uC3_7cycloa1kyl, —O(CH2)uC3_7cycloalkyl, C2_(, alkenyl, C1_(,
alkoxy, y—C1.6 alkyl, phenyl, C1.5 alkyl substituted with up
to 5 fluoro, and C1_(, alkoxy substituted with up to 5 fluoro, said C1-
6 alkyl, (CH2)uC3_7cycloalkyl, —O(CH2)uC3_7cycloalkyl, C24,
alkenyl, C1_(, alkoxy, hydroxy—C1.6 alkyl, and phenyl, each
ally substituted with one or more substituents each
independently selected from the group consisting of halo, cyano,
nitro, hydroxy, C1_(, alkyl, —(CH2)uC3_7cycloalkyl, C24, alkenyl,
C14, alkoxy, hydroxy—CH; alkyl, phenyl, C1_(, alkyl substituted with
up to 5 fluoro, and C1-5 alkoxy substituted with up to 5 fluoro, said
phenyl optionally substituted with one or more tuents each
ndently selected from the group consisting of halo, cyano,
nitro, y, C145 alkyl, —(CH2)uC3_7cycloa1ky1, C2_5 alkenyl,
C16 alkoxy, hydroxy—C1-6 alkyl, phenyl, CH; alkyl substituted with
up to 5 fluoro, and C1_(, alkoxy substituted with up to 5 fluoro;
R19 is aryl optionally substituted with one or more substituents
each independently selected from the group consisting of halo,
cyano, nitro, hydroxy, C1_(, alkyl optionally substituted with up to 5
fluoro, and C1.5 alkoxy optionally substituted with up to 5 fluoro;
R20 is hydrogen or aryl optionally tuted with one or more
substituents each independently selected from the group consisting
of halo, cyano, nitro, hydroxy, C1_(, alkyl optionally substituted
with up to 5 fluoro, and C1-6 alkoxy optionally tuted with up
to 5 fluoro; and
wherein when Y is NRgRg then R3 and R2 optionally come
together to be C1_3 alkyl g together as a ring,
with the proviso when R3 comes together with R2 to be C1_3 alkyl
linking together as a ring then R4, is not substituted with yl.
In one aspect, the CDC42 inhibitor may comprise Formula H, or a
pharmaceutically acceptable salt thereof
(Formula H)
wherein:
Y is NRgRg,
R8 is en; and R9 is C1_(, alkyl, said C1_(, alkyl, optionally
substituted with one or more substituents each ndently selected
from the group consisting of hydroxy, R19 or ORzo;
R19 is phenyl optionally substituted with one or more substituents each
independently selected from the group ting of halo, cyano, C1.5
alkyl optionally tuted with up to 5 fluoro, and C1.6 alkoxy
optionally substituted with up to 5 fluoro; and
R20 is hydrogen or phenyl optionally substituted with one or more
substituents each independently selected from the group consisting of
halo, cyano, nitro, hydroxy, C1.5 alkyl optionally substituted with up to
fluoro, and C1.6 alkoxy optionally substituted with up to 5 fluoro.
In one aspect, the CDC42 inhibitor may comprise Formula Ha
(CASIN), or a pharmaceutically acceptable salt thereof
m (Formula IIa)
In one aspect, the RHOA inhibitor may comprise (Formula III)(G04),
or a pharmaceutically acceptable salt thereof.
HEN”? ““2 H
\-".' 1 .
, \ _
)1; X?”I “my. #1»wang NN gray“ ¢ ”‘ch
y Ni},
s i.
‘ “:33? i} U j
“x”JK‘Nf
’ la HI)(GO4)
In one aspect, the composition may comprise the Formula 1b
(NSC23766) or a pharmaceutically acceptable salt thereof,
Formula IIa (CASIN) or a pharmaceutically acceptable salt f;
Formula HI (G04) or a pharmaceutically acceptable salt thereof, and
ations f.
Any amine, hydroxy, or carboxyl side chain on the compounds of the
may be esterified or amidified. The procedures and specific groups to
be used to achieve this end are known to those of skill in the art.
Synthesis of one or more of the above-referenced compounds may be
describes in, for example, US. Patent No. 124 to Zheng, issued
February 26, 2013; US. Patent No. 7,612,080 to Zheng et al., issued
November 3, 2009; and US. Patent No.7,517,890 to Zheng et a1,
issued April 14, 2009, the contents of which are incorporated by
reference for all purposes.
The active agent can form salts, which are also within the scope of the
red embodiments. Reference to a compound of the active agent
herein is understood to include reference to salts thereof, unless
otherwise indicated. The term “salt(s)”, as employed herein, denotes
acidic and/or basic salts formed with inorganic and/or organic acids
and bases. In addition, when an active agent contains both a basic
moiety, such as, but not limited to an amine or a pyridine or imidazole
ring, and an acidic moiety, such as, but not limited to a ylic acid,
zwitterions (“inner salts”) can be formed and are included within the
term “salt(s)” as used herein. Pharrnaceutically acceptable (e.g., non-
toxic, physiologically acceptable) salts are preferred, gh other
salts are also , e.g., in isolation or purification steps, which can
be employed during preparation. Salts of the nds of the active
agent can be formed, for example, by reacting a compound of the
active agent with an amount of acid or base, such as an equivalent
amount, in a medium such as one in which the salt precipitates or in an
aqueous medium followed by lyophilization.
The active agents which contain a basic moiety, such as, but not
limited to an amine or a pyridine or imidazole ring, can form salts with
a variety of organic and inorganic acids. ary acid addition salts
include acetates (such as those formed with acetic acid or trihaloacetic
acid, for example, trifluoroacetic acid), adipates, alginates, ascorbates,
aspartates, benzoates, benzenesulfonates, ates, borates, butyrates,
citrates, camphorates, camphorsulfonates, cyclopentanepropionates,
digluconates, dodecylsulfates, ethanesulfonates, tes,
glucoheptanoates, glycerophosphates, hemisulfates, heptanoates,
hexanoates, hydrochlorides (formed with hydrochloric acid),
hydrobromides (formed with en bromide), hydroiodides, 2-
WO 04809
hydroxyethanesulfonates, es, maleates (formed with maleic acid),
methanesulfonates (formed with methanesulfonic acid), 2-
naphthalenesulfonates, nicotinates, nitrates, oxalates, pectinates,
persulfates, ylpropionates, phosphates, picrates, pivalates,
nates, salicylates, succinates, sulfates (such as those formed with
sulfuric acid), sulfonates (such as those mentioned ), tartrates,
thiocyanates, toluenesulfonates such as tosylates, undecanoates, and
the like.
The active agents that contain an acidic , such as, but not limited
to a carboxylic acid, may form salts with a variety of organic and
inorganic bases. Exemplary basic salts include ammonium salts, alkali
metal salts such as , lithium, and potassium salts, alkaline earth
metal salts such as calcium and magnesium salts, salts with organic
bases (for example, organic amines) such as benzathines,
dicyclohexylamines, hydrabamines d with N,N-bis(dehydro—
abietyl)ethylenediamine], N—methyl—D-glucamines, N—methyl—D-
glucamides, t—butyl amines, and salts with amino acids such as
arginine, lysine and the like. Basic nitrogen-containing groups can be
quaternized with agents such as lower alkyl halides (e.g., methyl, ethyl,
propyl, and butyl chlorides, bromides and iodides), dialkyl sulfates
(e.g., dimethyl, diethyl, dibutyl, and diamyl sulfates), long chain
halides (e.g., decyl, lauryl, myristyl and stearyl chlorides, bromides
and iodides), aralkyl s (e.g., benzyl and phenethyl bromides), and
others.
Active agent, and salts f, can exist in their tautomeric form (for
example, as an amide or imino ether). All such tautomeric forms are
contemplated herein as part of the preferred embodiments.
] All stereoisomers of the present compounds, such as those, for
e, which can exist due to asymmetric carbons on any of the
substituents, including omeric forms (which can exist even in the
absence of asymmetric carbons) and diastereomeric forms, are
contemplated and within the scope of the preferred embodiments.
Individual stereoisomers of the compounds of the preferred
embodiments can, for example, be substantially free of other isomers,
or can be admixed, for example, as racemates or with all other or other
selected, isomers. The chiral centers of the preferred
embodiments can have the S or R configuration as defined by the
IUPAC 1974 Recommendations.
When the compounds are in the forms of salts, they may comprise
pharmaceutically acceptable salts. Such salts may include
pharmaceutically acceptable acid addition salts, ceutically
acceptable base addition salts, pharmaceutically acceptable metal salts,
ammonium and alkylated ammonium salts. Acid addition salts include
salts of inorganic acids as well as organic acids. Representative
examples of suitable inorganic acids include hydrochloric,
hydrobromic, hydroiodic, phosphoric, sulfuric, nitric acids and the like.
Representative examples of suitable organic acids include formic,
acetic, trichloroacetic, trifluoroacetic, propionic, benzoic, cinnamic,
citric, c, glycolic, lactic, maleic, malic, malonic, mandelic,
oxalic, picric, pyruvic, salicylic, succinic, esulfonic,
ethanesulfonic, tartaric, ascorbic, pamoic, bismethylene salicylic,
ethanedisulfonic, gluconic, citraconic, ic, stearic, palmitic,
EDTA, glycolic, p—aminobenzoic, ic, benzenesulfonic, p—
toluenesulfonic acids, sulphates, nitrates, phosphates, perchlorates,
borates, acetates, benzoates, hydroxynaphthoates, glycerophosphates,
ketoglutarates and the like. es of metal salts include lithium,
sodium, potassium, magnesium salts and the like. Examples of
ammonium and alkylated ammonium salts include ammonium,
methylammonium, dimethylammonium, trimethylammonium,
ethylammonium, hydroxyethylammonium, diethylammonium,
butylammonium, tetramethylammonium salts and the like. Examples
of organic bases include , arginine, guanidine, diethanolamine,
choline and the like.
The ceutically acceptable salts may be ed by s
known to one of ordinary skill in the art. For example, by reacting the
active agent with 1 to 4 lents of a base such as sodium
hydroxide, sodium methoxide, sodium hydride, potassium t—butoxide,
calcium hydroxide, magnesium hydroxide and the like, in solvents like
ether, THF, methanol, t—butanol, dioxane, panol, ethanol, etc.
Mixture of ts can be used. Organic bases like lysine, arginine,
diethanolamine, choline, guandine and their derivatives etc. can also be
used. Alternatively, acid addition salts Wherever applicable are
prepared by treatment with acids such as hloric acid,
hydrobromic acid, nitric acid, sulfuric acid, phosphoric acid, p-
toluenesulphonic acid, esulfonic acid, fonic acid, acetic acid,
citric acid, maleic acid salicylic acid, ynaphthoic acid, ic
acid, palmitic acid, succinic acid, benzoic acid, esulfonic acid,
tartaric acid and the like in solvents like ethyl acetate, ether, alcohols,
acetone, THF, dioxane, etc. Mixture of solvents can also be used.
In one aspect, any of the above-described compositions may comprise
a physiologically acceptable carrier. In one aspect, the physiologically
acceptable carrier may comprise a buffer. In one aspect, the
physiologically acceptable carrier may be selected from saline,
phosphate buffered saline, Tris ed saline, Hank's buffered saline,
water, or a combination thereof. In one aspect, the physiologically
acceptable carrier may comprise an electrolyte solution.
In one aspect, the RAC inhibitor, the CDC42 inhibitor, and the RHOA
inhibitor may be present in a carrier at a concentration, in ation
or separately, of at least about 10 ”M, or at least about 25 “M, at least
about 50 ”M, at least about IOOuM, at least about 200 ”M, at least
about 500 “M, at least about 1 mM, at least about 10 mM, at least
about 50 mM, at least about 100 mM, or at least about 1 M.
In one aspect, the RAC inhibitor may be t at a concentration of
from about 10 “M to about 500 uM, or from about 25 uM to about 400
11M, or from about 50 pM to about 300 uM, or from about 75 11M to
about 200 “M, or from about 100 ”M to about 150 “M, or about 50
] In one aspect, the CDC42 inhibitor may be present at a concentration
of from about 5 uM to about 500 uM, or from about 10 uM to about
400 ”M, or from about 25 tho about 300 pM, or from about 50 ”M
to about 200 “M, or from about 75 uM to about 150 “M, or about 10
In one aspect the RHOA inhibitor may be present at a concentration of
from about 10 pM to about 500 uM, or from about 25 pM to about 400
pM, or from about 50 “M to about 300 uM, or from about 75 ”M to
about 200 “M, or from about 100 uM to about 150 “M, or about 75
] In further aspects, the described compositions may comprise an
additive selected from NaCl, KCl, CaC12, MgClz, MgSO4, Na3 citrate,
citric acid, NaHC03, Na phosphate, Na acetate, Na gluconate, glucose,
maltose, mannitol, and combinations thereof. The described
compositions may comprise an additive selected from NaCl, KCl,
WO 04809
CaClz, MgClz, MgSO4, Na3 citrate, citric acid, NaHCO3, Na phosphate,
Na acetate, Na ate, glucose, maltose, mannitol, and
combinations thereof, wherein said additive may be present in an
amount of from about 0.5 mmol/L to about 150 mmol/L.
In further aspects, the described compositions may comprise one or
more ingredients selected from D-ribose, D-glucose, Hanks solution,
Hepes solution, bovine serum albumin, tic anticoagulant peptide and
sterile water, or combinations thereof.
In one aspect, the composition may comprise an ary substance
selected from pH adjusting and buffering agents, tonicity adjusting
agents, stabilizers, wetting agents, and ations thereof.
In one aspect, the composition may have a pH of from about 5 to about
8, or from about 6 to about 7, or about 6.8 to about 7.4.
In one aspect, the composition may be isotonic.
In yet further aspects, the composition may comprise an additional
therapeutic agent.
A method for storing platelets is also described. In this aspect, the
method comprises the step of g ets in a composition as
disclosed herein.
In one aspect, the method may comprise ting platelets with a
solution comprising an RAC tor, an CDC42 inhibitor, and/or a
RHOA inhibitor, n the one or more actives are present in a
carrier at a concentration, in ation or separately, of at least
about 10 uM, or at least about 25 uM, at least about 50 uM, at least
about 100pM, at least about 200 ”M, at least about 500 ”M, at least
about 1 mM, at least about 10 mM, at least about 50 mM, at least about
100 mM, or at least about 1 M.
In one aspect, the method may se contacting platelets with a
solution comprising an RAC inhibitor present in a solution at a
concentration of from about 10 uM to about 500 “M, or from about 25
“M to about 400 ”M, or from about 50 uM to about 300 “M, or from
about 75 “M to about 200 “M, or from about 100 uM to about 150
pM, or about 50 uM.
In one aspect, the method may comprise contacting platelets with a
solution comprising a CDC42 inhibitor present in a solution at a
concentration of from about 5 “M to about 500 ”M, or from about 10
“M to about 400 uM, or from about 25 uM to about 300 “M, or from
about 50 uM to about 200 “M, or from about 75 [AM to about 150 uM,
or about 10 “M.
In one aspect, the method may comprise contacting platelets with a
solution comprising an RHOA inhibitor present in a on at a
concentration of from about 10 ”M to about 500 “M, or from about 25
pM to about 400 ”M, or from about 50 uM to about 300 ”M, or from
about 75 ”M to about 200 “M, or from about 100 ”M to about 150
“M, or about 75 “M.
In one aspect, the storage step may be carried out at a temperature of
from about 1°C to about 20°C, or at about 1°C, or about 2°C, or about
3°C, or about 4°C, or about 5°C, or about 6°C, or about 7°C, or about
8°C, or about 9°C, or about 10°C, or about 11°C, or about 12°C, or
about 13°C, or about 14°C, or about 15°C, or about 16°C.
Ine aspect, the storage step may be carried out for a period of time of
from about 7 to 20 days, or from about 10 to 15 days, or greater than 7
days, or greater than 8 days, or greater than 9 days, or greater than 10
days, or greater than 11 days, or r than 12 days, or greater than
13 days, or greater than two weeks.
In one , the composition may be used in an amount sufficient to
inhibit a platelet damaging activity selected from polymerization of F—
actin, depolymerization of n, actomyosin contraction, n
polymerization, spectn'n anchorage, or combinations thereof.
In one aspect, applying the described s, the platelet survival
may be greater than about 65%, or greater than about 70%, or greater
than about 75%, or greater than about 80%, or greater than about 85%,
or greater than about 90%, or greater than about 95%, or greater than
about 99% after a storage period of 24 hours at 5C.
In one aspect, a method of reversing platelet activation is also
disclosed, comprising contacting ted platelets with a composition
as described herein. In one aspect, the ting step may be canied
out at a ature of about 0°C. In a yet further aspect, the disclosed
compositions may be used to reverse refrigeration storage lesions in
platelets. In this aspect, platelets having refrigeration storage lesions
may be contacted with a composition as disclosed herein, for a period
of time sufficient to reverse refrigeration storage lesions.
Examples
Applicant has tested the ability of three chemical inhibitors, CASIN,
NSC23766 and G04, targeting Cdc42, Racl and RhoA, respectively
(FIG 2), to t the activity of the GTPases and the consequent
cytoskeleton-dependent functions of human platelets. A rationally
developed inhibitor of Cdc42 with activity on activation by guanine
nucleotide exchange factors is CASIN (29, Nature Biotech under
revision). CASIN was ly discovered by Zheng group as a small
le that recognizes a pocket domain that ically blocks the
ability of GEF interaction with Cdc42 (FIG 3A). CASIN is found to
suppress of hematopoietic stem cell aging through its specific Cdc42
inhibitory activity (29). In platelets, it inhibits Cdc42 activation (FIG
3B) and prevents collagen-induced platelet shape changes (FIG 3C).
These s depend on integrin signaling and involve F—actin
rization and filopodia formation as demonstrated by phalloiding
staining (FIG 3C, lower panels). Cdc42 inhibition by CASIN results in
prevention of collagen-induced platelet ation (FIG 3D) that can
be reversed by a washout of the inhibitor (FIG 3D, upper and lower
panels).
Similarly, Applicant has identified an inhibitor of Rac, NSC23766 (30—
34), with an ability to impair Racl activation by le activating
signals which may be l in platelet signaling associated with
Gpr/GpX (35). NSC23766 was discovered in a structure-based
virtual screening of compounds that fit into a surface groove of Racl
known to be critical for guanine nucleotide exchange factor
specification (34) (FIG 4A). NSC23766 can effectively block Racl
activation (FIG 4B) and Rac-dependent cytoskeletal rearrangements
(actin lamellopodia) of platelets stimulated by collagen (30, 32, 35),
indicating its ability for ssing collagen-integrin dependent
signaling (FIG 4C). Finally, 66 reversibly inhibits, in a dose-
dependent fashion, platelet aggregation d by collagen (FIG 4D,
upper and lower panels).
Finally, G04/Rhosin was also developed by us as a RhoA GTPase
activation site inhibitor that transiently and specifically blocks RhoA
activity and RhoA-mediated signaling functions (36, 37). G04 ns
two aromatic rings tethered by a , and it binds to the surface area
sandwiching Trp58 of RhoA (FIG 5A) with a submicromolar Kd and
effectively ts GEF-catalyzed RhoA activation. In platelets, G04
2015/066252
specifically inhibits en-induced RhoA activity (FIG 5B) and
RhoA-mediated ar functions including fibrinogen-dependent
platelet spreading (FIG 5C) and collagen-dependent platelet
ation (FIG 5D). Effect by collagen or thrombin is reversible
(FIG 5D, lower).
In addition to the reversibility, each inhibitor transiently mimics the
effects of Cdc42, Racl, or RhoA gene knockout in ets,
respectively, and does not show any additive effects in the respective
knockout cells (data not shown), indicating their specificity and a lack
of toxicity.
A combination of CASIN (10 uM), G04 (75 uM) and/or NSC23766
were used in C57Bl/6 murine carboxyfluorescein—lateled platelets
incubated at 0°C or 5°C for 3.5 hours. After re—warming, platelets were
infused in 5 congenic mice (per group) and compared with control
(room temperature stored) and refrigerated, ted platelet group
(FIG 7). While the combination of NSC23766, G04 and CASIN result
in close—to-complete reversal of the survival deficiency induced by
refrigerated storage, NSC23766 alone or NSC23766 in combination
with CASIN or G04 did not result in significant reversal of the e
lesion of platelets (Figure 7). In a second experiment focused on the
specific ations with more activity to reverse the survival
impairment associated with the use of Rho GTPase inhibitors, we
analyzed the 24-hour recovery (%) and survival (hours) of platelets
that had been stored in presence of several combinations of drugs
(Figure 6A).
Similarly, treatment of refrigerated platelets with CASIN or G04 alone
did not improve platelet r recovery (FIG 6B) or survival (FIG
6C) in vivo. However, a triple combination of CASIN, G04 and
NSC23766 resulted in a significant improved ry (FIG 6B) and
survival (FIG 6C) of refrigerated platelets after infusion. Use of the
same triple inhibitor combination during storage of refrigerated
platelets at 5°C instead of 0°C resulted in complete reversal of the
recovery and survival of refrigerated platelets in vivo (FIG 6D) as
determined by hit regression analysis (COSTCO software) and
ANOVA test with Bonferroni correction for statistical differences.
Applicant found that the r recovery of platelets refrigerated was
significantly reduced (~20%) compared with the group control (stored
at room temperature, p<0.01). stingly, the shortened recovery
was completely reversed by incubation with the cocktail of three
inhibitors (FIG 6D). Altogether, these data indicate that the inhibitory
ation of Cdc42, Racl, and RhoA with CASIN, NSC23766 and
G04 can specifically and reversibly inhibit platelet activation and may
be useful in a reversal of refrigeration e lesion in platelets.
Finally, Rho family GTPase inhibitors can prevent human platelet
storage lesion in vitro as assessed by article ion and
content of Gpr (CD42b) in microparticles. Applicant found that the
use of tors resulted in reversal of the refrigeration dependent
microparticle generation (Figure 8A—B). Finally, Applicant analyzed
the formation of lipid raft microdomains on the platelet membrane by
differential analysis in lysates enriched in Triton—X—lOO resistant
membrane fragments in human platelets stored refrigerated for 3 and 7
days e 9). We found a complete correlation between the results
of survival of erated platelets in presence of inhibitor
ations with the formation of lipid raft microdomains,
suggesting that the inhibitor combination containing G04, NSC23766
and CASIN s in reversal of refrigeration-induced lipid raft
formation. Interestingly, washing out GO4, NSC23766 and CASIN
s in restoration of the same levels of lipid rafts as found in 3 or 7
day stored ets at room temperature (Figure 9), suggesting that the
removal of these inhibitors results in platelet membrane rheological
modifications similar to the ones observed in unprocessed, standard
storage platelets for the same period of time (Figure 9). These data
provide proof-of—concept that the long-term storage (6 days) of
platelets in plasma containing Rho GTPase inhibitors is not rious
of platelets but can further prevent their storage lesion-associated
activation.
Thus, Applicant’s data strongly support that reversible inhibition of
multiple Rho family of GTPases by chemical inhibitors can
significantly t refrigerated storage damage and improve platelet
survival and transfusion function after refrigeration by interference
with lipid raft microdomain formation, actomyosin cs and GPIb
clustering in membrane microdomains.
Applicant further analyzed and confirmed that the reversible inhibition
of multiple Rho family of GTPases by chemical tors can
significantly prevent refrigerated storage damage and improve platelet
survival and transfusion function after refrigeration. The ism is
believed to be through ting Rho GTPase—regulated lipid raft
microdomain formation, actomyosin dynamics and GPIb clustering in
ne omains.
To further validate our results from murine refrigerated platelet
survival improvement in primates, Applicant first analyzed the survival
of human pooled (n=10 donors per experiment) platelets transfused in
inbred thrombocytopenic, irradiated, hage-depleted NSG mice.
These immunodeficient mice allow the survival of human platelets for
a short period of time (<24 hours) but sufficiently long to allow
comparison. In this model, Applicant found that, in two independent
experiments (n=4 mice per group and ment), the incubation of
platelets during storage with the inhibitors G04 (RhoA inhibitor),
NSC23766 (NSC; Rac inhibitor) in absence of wash step or with a
wash step at room temperature of the inhibitors used in vitro.
Interestingly, Casin (Cdc42 inhibitor) did not modify the poor survival
of refrigerated platelets (FIG 10A-10B). Secondly, these results were
further ted by applying a combination of G04, NSC and Casin in
outbred Rhesus monkey platelets that were biotinylated and
autologously transfused after 7—day refrigerated storage. As seen in
FIG 10C, a randomized, crossover trial where the same monkeys were
transfused with control (not treated with inhibitors, control) or
inhibitors (test), demonstrated that the inhibitor combination resulted
in improved (positive recoveries) in the test group.
To better define the effect of RhoA inhibition and to rule out any off-
target effect of G04, we analyzed ets from wild-type (Wt) mice
and from mice with interferon-induced (polylzC) genetic deficiency of
RhoA (FIG 11A). G04, and to a lesser degree NSC, were able to
reduce the level of Flot—l in the membrane lipid raft (microdomains) of
refrigerated Wt platelets (FIG 11B). Interestingly, the levels of
membrane-bound Flot-l in RhoA—deficient (RhoANA) platelets was
r to those found in G04 treated Wt refrigerated platelets (FIG
10C), and NSC does not appear to add any significant further
inhibition.
Next, Applicant analyzed r the phagocytosis of refrigerated
murine platelets by activated monocytic THP—1 cells was modified by
pre-treatment with the Rho family inhibitors. Pre—treatment of
refrigerated platelets with G04 or the combination of G04, Casin and
NSC reduce the y to be recognized by activated THP—1 cells (FIG
12A). Use of murine RhoA genetically deficient platelets (FIG 12A,
inset) were ant to the phagocytosis induced by eration and
showed no response to G04 or the ation of G04, Casin and NSC
(FIG 12A). These results strongly indicate that G04 blocks the ability
of refrigerated platelets to present ligands susceptible of recognition by
hage cells and this effect is exclusively dependent on RhoA
activity. These results were confirmed in human platelets.
Phagocytosis by THP—1 cells of refrigerated human platelets was
completely prevented by storage with G04 or combination of G04,
Casin and NSC even after wash out of the inhibitors at room
temperature (FIG 12B).
Finally, Applicant examined whether the absence of translocation of
lipid raft microdomains to the membrane (FIG 9) ates with
changes in galactosyl-transferase and sialyl-transferase activities.
These activities should reduce by transfer to other substrates the
galactosyl and sialyl residues of Gpr on the membrane, a crucial step
in the s of refrigeration storage lesion of platelets. Applicant
found that G04 or G04 in combination with Casin and NSC completely
prevented the presence of osyl- (FIG 12C) or sialyl— (FIG 12D)
transferase activities on the platelet membrane. This effect is
completely reversible since washing of the inhibitors restores the
transport of these enzymes to the membrane (FIG 12C-D).
Altogether, these new data strongly support the sion that Rho
GTPase inhibitor G04 alone or G04 in combination with NSC23766
WO 04809
and/or Casin will prevent refrigerated e lesion of platelets. This
effect is reproduced in mouse, human and non-human primate
platelets. The mechanism involves the prevention of formation of
galactosyl— and sialyl—transferase rich membrane lipid rafts on
refrigerated platelet membranes through a modulation of actomyesin
dynamics.
All percentages and ratios are calculated by weight unless otherwise
indicated.
All percentages and ratios are calculated based on the total
ition unless otherwise indicated.
It should be understood that every maximum numerical limitation
given throughout this specification includes every lower numerical
tion, as if such lower numerical limitations were expressly
written herein. Every m numerical limitation given throughout
this specification will include every higher numerical limitation, as if
such higher numerical limitations were expressly written . Every
numerical range given throughout this specification will include every
narrower numerical range that falls within such broader numerical
range, as if such narrower cal ranges were all expressly written
herein.
The dimensions and values disclosed herein are not to be understood as
being strictly limited to the exact numerical values recited. Instead,
unless otherwise specified, each such ion is intended to mean
both the recited value and a functionally equivalent range surrounding
that value. For example, a dimension disclosed as “20 mm” is intended
to mean “about 20 mm.”
Every document cited herein, including any cross referenced or related
patent or ation, is hereby incorporated herein by reference in its
entirety unless expressly excluded or otherwise limited. The citation of
any document is not an admission that it is prior art with t to any
invention disclosed or claimed herein or that it alone, or in any
combination with any other reference or references, teaches, suggests
or discloses any such invention. r, to the extent that any meaning
or definition of a term in this document conflicts with any meaning or
definition of the same term in a document incorporated by reference,
the meaning or definition assigned to that term in this document shall
govern.
While particular ments of the present invention have been
illustrated and described, it would be s to those skilled in the art
that various other changes and modifications can be made without
departing from the spirit and scope of the invention. It is therefore
intended to cover in the appended claims all such changes and
modifications that are within the scope of this invention.
What is claimed is:
1. A composition, comprising platelets, a RHOA inhibitor selected from:
, or a salt f,
, or a salt thereof,
or combinations thereof; and
an acceptable carrier.
2. The composition according to claim 1, wherein the carrier comprises a buffer.
3. The composition according to claim 1 or 2, wherein the carrier is selected
from saline, phosphate-buffered saline, tris-buffered saline, Hank’s buffered
saline, water, or a combination thereof.
4. The composition according to any one of claims 1-3, wherein the carrier
comprises an electrolyte solution.
. The composition according to any one of claims 1-4, further comprising an
additive selected from NaCl, KCl, CaCl2, MgCl2, MgSO4, sodium citrate,
citric acid, NaHCO3, sodium phosphate, sodium e, sodium gluconate,
glucose, maltose, mannitol, D-ribose, D-glucose, Hank’s solution, HEPES
solution, bovine serum albumin, tick anticoagulant peptide and sterile water, a
pH adjusting agent, a pH buffering agent, a ty adjusting agent, a
stabilizer, a g agent, and combinations f.
6. The composition according to claim 5, wherein the additive comprises a
sodium ion, potassium ion, acetate ion, magnesium ion, chloride
ion, gluconate ion, glucose, ate ion, citrate ion, calcium ion, and
combinations f.
1003747565
7. The composition according to claim 5 or 6, n said additive is t in
an amount of from 0.5 mmol/L to 150 mmol/L.
8. The composition according to any one of claims 1-7, wherein the pH of the
composition is from 5 to 8.
9. The composition according to any one of claims 1-8, wherein the composition
is isotonic.
. The ition ing to any one of claims 1-9, further comprising a
therapeutic agent.
11. The composition according to any one of claims 1-10, wherein the RHOA
inhibitor is , or a salt thereof.
12. The composition according to any one of claims 1-10, wherein the RHOA
inhibitor is , or salt thereof.
13. The composition according to any one of claims 1-12, wherein the RHOA
inhibitor is present at a concentration of at least 10 μM.
14. The composition according to any one of claims 1-13, wherein the RHOA
inhibitor is present at a concentration of from 10 μM to 500 μM.
. The composition according to any one of claims 1-14, wherein the RHOA
inhibitor is present at a tration of from 25 μM to 400 μM.
16. The composition ing to any one of claims 1-15, wherein the RHOA
inhibitor is present at a concentration of from 50 μM to 300 μM.
17. The composition according to any one of claims 1-16, wherein the RHOA
inhibitor is present at a concentration of from 75 μM to 200 μM.
18. The composition according to any one of claims 1-17, wherein the RHOA
inhibitor is present at a concentration of from 100 μM to 150 μM.
19. A method for storing platelets comprising forming the composition of any one
of claims 1-18, and storing said composition.
1003747565
. A method of reversing platelet activation comprising forming the composition
of any one of claims 1-18, wherein the platelets added to the composition are
activated.
21. A method of reversing refrigeration storage lesion in ets comprising
forming the composition of any one of claims 1-18, wherein the platelets in
the composition have eration storage lesions prior to preparation of the
composition.
22. A method for slowing platelet damage comprising forming the composition of
any one of claims 1-18.
23. The method according to any one of claims 19-22, wherein the composition is
stored in cold storage at 1 °C to 20 °C.
24. The method according to any one of claims 19-22, wherein the composition is
stored in cold storage at 1 °C to 15 °C.
. The method according to any one of claims 19-22, wherein the composition is
stored in cold storage at 1 °C.
26. The method according to any one of claims 19-25, wherein the composition is
stored in cold e for a period of time from 7 to 20 days.
27. The method according to any one of claims 19-25, n the composition is
stored in cold storage for a period of time from 10 to 15 days.
28. The method according to any one of claims 19-24, wherein platelet survival is
greater than 65% after a storage period of 24 hours at 5 °C.
29. The method according to any one of claims 19-24, wherein platelet survival is
greater than 95% after a storage period of 24 hours at 5 °C.
. The method according to any one of claims 19-29, wherein the composition
ts platelet damaging activity wherein the platelet damaging activity is
selected from: polymerization of F-actin, depolymerization of F-actin,
actomyosin contraction, tubulin polymerization, and spectrin anchorage.
31. The method ing to any one of claims 19-30, n the RHOA
inhibitor or salt thereof is the only et preserving ingredient.
32. Use of the composition of any one of claims 1-18 in the manufacture of a
medicament for administering ets to a subject in need thereof.
1003747565
33. The use of claim 32, wherein the medicament is for infusion of the platelets in
the subject in need f.
34. The use of claim 32, wherein the medicament is for transfusion of the platelets
into the subject in need thereof, wherein the platelet survival upon transfusion
is improved.
. The use according to any one of claims 32-34, n the RHOA inhibitor or
a salt thereof is essentially the only platelet preserving ingredient.
36. Use of a RHOA inhibitor selected from:
, or a salt thereof,
, or a salt thereof,
or combinations thereof
and one or more platelets
in the manufacture of a ment sing a composition according to
any one of claims 1-18 for ing platelet survival upon transfusing
platelets into a subject, wherein the platelet survival improvement is in
comparison with the tage platelet survival for platelets that are not
contacted with at least one of the aforementioned RHOA inhibitors.
37. The use of claim 36, wherein the RHOA inhibitor or a salt thereof is the only
platelet preserving ingredient.
1003747565
1/11
FIG 1
A B
GpIb
“Cold receptor”
cluster
Cold
Lipid raftfilopodia
Lipid raftlamellipodia
Cdc42
Stress fibers
Uncapping actin assembly Actomyosin
Increase [Ca2+ ]
Tubulin depolymerized
Loss of spectrin anchorage
GpIb clustering
FIG 2
Rho GTPase Inhibitors
COMPOUNDS TARGET
66 RAC
CASIN CDC42
G04 RHOA
1003747571
2/11
FIG 3.
A D
B D
7571
3/11
FIG 4.
A D
NSC23766 NSC23766 (M)
Leu67 c
Leu70Pro73Gln74
Arg68Ser71
Tyr64 Lys5
Asp59 Asp76
Thr58Val7Trp56 a
Gly54
Asp57 r
Rac1 f
NSC23766 treated,
B p
then washed out
No 66 s
C 0 M NSC23766 50 M NSC23766 s
1003747571
4/11
FIG 5.
A C
7571
/11
FIG 6
37 C RT 0-5 C RT
Treatment
0 C-Control
0 C-G04
0 C-Casin
0 C-Casin/
* G04/NSC23766
Platelet ry (%) 100
0 20 40 60 80
Time (hours post-infusion)
1003747571
6/11
FIG 7
8847
7/11
FIG 8
8847
8/11
FIG 9
7571
9/11
FIG 10
7571
/11
FIG 11
7571
11/11
FIG 12
7571
Claims (37)
1. A composition, comprising platelets, a RHOA inhibitor selected from: , or a salt f, , or a salt thereof, or combinations thereof; and an acceptable carrier.
2. The composition according to claim 1, wherein the carrier comprises a buffer.
3. The composition according to claim 1 or 2, wherein the carrier is selected from saline, phosphate-buffered saline, tris-buffered saline, Hank’s buffered saline, water, or a combination thereof.
4. The composition according to any one of claims 1-3, wherein the carrier comprises an electrolyte solution.
5. The composition according to any one of claims 1-4, further comprising an additive selected from NaCl, KCl, CaCl2, MgCl2, MgSO4, sodium citrate, citric acid, NaHCO3, sodium phosphate, sodium e, sodium gluconate, glucose, maltose, mannitol, D-ribose, D-glucose, Hank’s solution, HEPES solution, bovine serum albumin, tick anticoagulant peptide and sterile water, a pH adjusting agent, a pH buffering agent, a ty adjusting agent, a stabilizer, a g agent, and combinations f.
6. The composition according to claim 5, wherein the additive comprises a sodium ion, potassium ion, acetate ion, magnesium ion, chloride ion, gluconate ion, glucose, ate ion, citrate ion, calcium ion, and combinations f. 1003747565
7. The composition according to claim 5 or 6, n said additive is t in an amount of from 0.5 mmol/L to 150 mmol/L.
8. The composition according to any one of claims 1-7, wherein the pH of the composition is from 5 to 8.
9. The composition according to any one of claims 1-8, wherein the composition is isotonic.
10. The ition ing to any one of claims 1-9, further comprising a therapeutic agent.
11. The composition according to any one of claims 1-10, wherein the RHOA inhibitor is , or a salt thereof.
12. The composition according to any one of claims 1-10, wherein the RHOA inhibitor is , or salt thereof.
13. The composition according to any one of claims 1-12, wherein the RHOA inhibitor is present at a concentration of at least 10 μM.
14. The composition according to any one of claims 1-13, wherein the RHOA inhibitor is present at a concentration of from 10 μM to 500 μM.
15. The composition according to any one of claims 1-14, wherein the RHOA inhibitor is present at a tration of from 25 μM to 400 μM.
16. The composition ing to any one of claims 1-15, wherein the RHOA inhibitor is present at a concentration of from 50 μM to 300 μM.
17. The composition according to any one of claims 1-16, wherein the RHOA inhibitor is present at a concentration of from 75 μM to 200 μM.
18. The composition according to any one of claims 1-17, wherein the RHOA inhibitor is present at a concentration of from 100 μM to 150 μM.
19. A method for storing platelets comprising forming the composition of any one of claims 1-18, and storing said composition. 1003747565
20. A method of reversing platelet activation comprising forming the composition of any one of claims 1-18, wherein the platelets added to the composition are activated.
21. A method of reversing refrigeration storage lesion in ets comprising forming the composition of any one of claims 1-18, wherein the platelets in the composition have eration storage lesions prior to preparation of the composition.
22. A method for slowing platelet damage comprising forming the composition of any one of claims 1-18.
23. The method according to any one of claims 19-22, wherein the composition is stored in cold storage at 1 °C to 20 °C.
24. The method according to any one of claims 19-22, wherein the composition is stored in cold storage at 1 °C to 15 °C.
25. The method according to any one of claims 19-22, wherein the composition is stored in cold storage at 1 °C.
26. The method according to any one of claims 19-25, wherein the composition is stored in cold e for a period of time from 7 to 20 days.
27. The method according to any one of claims 19-25, n the composition is stored in cold storage for a period of time from 10 to 15 days.
28. The method according to any one of claims 19-24, wherein platelet survival is greater than 65% after a storage period of 24 hours at 5 °C.
29. The method according to any one of claims 19-24, wherein platelet survival is greater than 95% after a storage period of 24 hours at 5 °C.
30. The method according to any one of claims 19-29, wherein the composition ts platelet damaging activity wherein the platelet damaging activity is selected from: polymerization of F-actin, depolymerization of F-actin, actomyosin contraction, tubulin polymerization, and spectrin anchorage.
31. The method ing to any one of claims 19-30, n the RHOA inhibitor or salt thereof is the only et preserving ingredient.
32. Use of the composition of any one of claims 1-18 in the manufacture of a medicament for administering ets to a subject in need thereof. 1003747565
33. The use of claim 32, wherein the medicament is for infusion of the platelets in the subject in need f.
34. The use of claim 32, wherein the medicament is for transfusion of the platelets into the subject in need thereof, wherein the platelet survival upon transfusion is improved.
35. The use according to any one of claims 32-34, n the RHOA inhibitor or a salt thereof is essentially the only platelet preserving ingredient.
36. Use of a RHOA inhibitor selected from: , or a salt thereof, , or a salt thereof, or combinations thereof and one or more platelets in the manufacture of a ment sing a composition according to any one of claims 1-18 for ing platelet survival upon transfusing platelets into a subject, wherein the platelet survival improvement is in comparison with the tage platelet survival for platelets that are not contacted with at least one of the aforementioned RHOA inhibitors.
37. The use of claim 36, wherein the RHOA inhibitor or a salt thereof is the only platelet preserving ingredient.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462013662P | 2014-06-18 | 2014-06-18 | |
US14/743,213 | 2015-06-18 | ||
US14/743,213 US10028503B2 (en) | 2014-06-18 | 2015-06-18 | Platelet storage methods and compositions for same |
PCT/US2015/066252 WO2016204809A1 (en) | 2014-06-18 | 2015-12-17 | Platelet storage methods and compositions for same |
Publications (2)
Publication Number | Publication Date |
---|---|
NZ738372A NZ738372A (en) | 2021-11-26 |
NZ738372B2 true NZ738372B2 (en) | 2022-03-01 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2020223650B2 (en) | Platelet storage methods and compositions for same | |
IL264516A (en) | Isocitrate dehydrogenase inhibitor compounds, compositions comprising same and uses thereof | |
ZA200608712B (en) | Substantially pure 2-{[2-(2-methylamino-pyrimidin-4-yl)-1II-indole-5-carbonyl]-amino}-3-(phenylpyridin-2-yl-amino)-propionic acid as an IkB kinase inhibitor | |
MX2011000026A (en) | Protein kinase inhibitors. | |
EP2994140A2 (en) | Methods for treating hcv infection | |
JP2021531310A (en) | Boronic acid derivative | |
AU2014283774B2 (en) | 1,3-diaminocyclopentane carboxamide derivatives | |
US11447497B2 (en) | (S)-3-(2-(4-(benzyl)-3-oxopiperazin-1-yl)acetamido)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid derivatives and related compounds as caspase inhibitors for treating cardiovascular diseases | |
EP3310761B1 (en) | Platelet storage methods and compositions for same | |
NZ738372B2 (en) | Platelet storage methods and compositions for same | |
JP2022523355A (en) | Compounds and Methods of Deuterated Xanomeline for the Treatment of Neuropathy | |
CA2887420C (en) | Matrix metalloproteinase inhibitors and methods for the treatment of pain and other diseases | |
ES2263835T3 (en) | COMBINED THERAPY AGAINST TUMORS UNDERSTANDING DERIVED FROM DISTAMYCIN ACRILOIL SUBSTITUTED AND INHIBITORS PROTEIN QUINASE (SERINE / TREONINE QUINASE). | |
IL262597A (en) | Piperidinyl derivatives, their preparation and use | |
WO2023166078A1 (en) | Combination treatments comprising a ctps1 inhibitor and a chek1 inhibitor | |
JP2022524077A (en) | Azetidinyl O-glycoprotein-2-acetamide-2-deoxy-3-D-glucopyranosidase inhibitor | |
TW202340173A (en) | Inhibitors of cysteine proteases and use thereof | |
OA19479A (en) | Combination therapy. | |
CA2722007A1 (en) | Five-membered ring compound | |
JP2021532149A (en) | Pyrolo [2,3-B] pyridine derivative as an influenza virus replication inhibitor | |
EP1790345A1 (en) | Triazin beta-secretase inhibitors | |
WO2009140464A1 (en) | Methods of administration of thrombopoietin mimetic compounds |